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Abstract
The role of Mdm2 in estrogen-mediated breast cancer cell proliferation
by
Angelika Brekman
Adviser: Dr. Jill Bargonetti
Estrogen signaling is important in breast cancer development and progression. Mdm2, a
negative regulator of the p53 tumor suppressor, is often over-expressed in estrogen receptor
positive breast cancers. To study the role of Mdm2 in the estrogen-mediated breast cancer cell
proliferation, we examined the effect of estrogen on the p53-Mdm2 pathway in estrogen receptor
positive and p53 wild-type MCF-7 breast cancer cells. Estrogen-mediated increase in cell
proliferation correlated with increased Mdm2, but no concomitant decrease in the p53 protein
level. Blocking Mdm2 expression with inducible shRNA inhibited estrogen-mediated cell
proliferation and colony formation in soft agar. Mdm2 knockdown in the presence of estrogen
increased p21 and the percent of cells in the G1 phase. Interestingly, knockdown of p53 had no
effect on the estrogen-mediated cell proliferation. Estrogen also up-regulated the Mdm2 protein
levels in cells exposed to the DNA damaging agent, etoposide, and the Mdm2 inhibitor, Nutlin-3.
In turn, estrogen inhibited etoposide- and Nutlin-3-induced transcription of puma, a proapoptotic p53 target gene, without changing the p53 protein levels or p53 recruitment to the
chromatin. The decrease in puma gene transcription correlated with a decrease in Puma protein
and an increase in Bcl-2 protein, an anti-apoptotic estrogen receptor target. Overall, our findings
suggest that estrogen signals to an Mdm2-mediated pathway to provoke cell proliferation and
that this pathway is associated with inhibition of the G1 checkpoint.
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CHAPTER 1:
INTRODUCTION
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1.1 Discovery and functions of Mdm2
The murine double minute 2 (mdm2) gene was discovered on double minute
chromosomes (acentromeric extrachromosomal nuclear bodies) in a spontaneously transformed
mouse BALB/c cell line (3T3-DM), a derivative of the NIH-3T3 cell line (Cahilly-Snyder et al.
1987). The mdm2 gene was found to be over-expressed by amplification greater than 50-fold, to
provide growth advantage and to promote spontaneous transformation (Fakharzadeh et al. 1991).

Figure 1: Domain structures of Mdm2. p53 binding domain, nuclear localization signal (NLS),
nuclear export signal (NES), acidic domain, zinc finger domain and RING finger domain (Lee
and Gu 2010).
Biochemically, the Mdm2 protein functions as an E3 ubiquitin ligase (Honda et al. 1997).
The RING motif is common in E3 ligases and is responsible for the E3 ligase activity of Mdm2
(Figure 1). The main p53 interaction domain is encoded by the N terminus 100 amino acids of
Mdm2, which binds the N terminal transactivation domain of p53. More recently, the N terminus
of Mdm2 has also been shown to interact with the C terminus of p53 (Poyurovsky et al. 2010).
The nuclear localization and nuclear export signals shuttle Mdm2 back and forth between the
cytoplasm and the nucleus. The central region of Mdm2 contains an acidic domain and a zinc
finger domain. A number of proteins have been shown to interact with this region of Mdm2,
including L5, L11 and L26 ribosomal proteins, p14ARF and Rb tumor suppressors, and the
acetyltransferase p300 (Bouska and Eischen 2009). The acidic domain of Mdm2 has also been
shown to interact with the central region of p53, the DNA binding domain, and this interaction
was shown to be essential for p53 ubiquitination by Mdm2 (Ma et al. 2006, Wallace et al. 2006).
2

The C terminus of Mdm2 contains the RING finger domain, which is responsible for the
ubiquitin ligase function of Mdm2 and also serves as a binding site for the MdmX protein, an
Mdm2 homolog (Tanimura et al. 1999).

1.2 The role of Mdm2 in the p53 pathway
1.2.1 p53 functions as a tumor suppressor
The p53 tumor suppressor primarily acts as a transcription factor (Riley et al. 2008)
inducing over 200 known target genes (Wei et al. 2006, Zhao et al. 2000). Through its DNA
binding domain, p53 associates with consensus response elements, located in promoters and
intronic sequences of numerous genes, and regulates their expression (Laptenko and Prives
2006). Many of these genes encode proteins that control cell cycle progression, senescence,
DNA repair and apoptosis (Vousden and Prives 2009) (Figure 2). Stressful stimuli, such as DNA
damage and oncogene activation, lead to p53 activation and subsequent up-regulation of its
target genes expression (Levine et al. 2006). Additionally, non-transcriptional activities of p53
have been implicated in its apoptotic response where p53 has a direct function in the intrinsic
mitochondrial cell death pathway (Vaseva and Moll 2009).
p53 is considered to be an important barrier to tumor development because it prevents
proliferation of cells that have sustained DNA damage and/or have abnormally active oncogenes
(Meek 2009). Probably for this reason, in over 50% of all human cancers the p53 gene is found
to be mutated or completely deleted (Hollstein et al. 1991, Vogelstein et al. 2000). However, in
addition to mutations in the p53 gene, p53 may be compromised through improper activity of the
p53 negative regulators.

3

Figure 2: Activation of p53 and cellular responses. Stress signals activate various kinases and
acetyltransferases, which post-translationally modify p53. This stabilizes p53 and activates p53
transcriptional activity, where p53 interacts with sequence specific DNA binding sites of its
target genes. The transcriptional activation leads to diverse cellular responses such as
apoptosis, cell-cycle arrest and DNA repair. When p53 is no longer needed, it is targeted for
ubiquitination by Mdm2 and is degraded by the proteasome. p53 can also act outside of the
nucleus to induce apoptosis by binding with anti-apoptotic proteins such as Bcl-2. (From (Bode
and Dong 2004)).
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1.2.2 The p53-Mdm2 auto-regulatory feedback loop
Under normal conditions, the p53 tumor suppressor activity is inhibited. Mdm2 is a major
negative regulator of p53. Soon after its discovery, Mdm2 was shown to form a complex with the
tumor suppressor p53 concealing its transactivation domain and inhibiting p53 transcriptional
activity (Barak and Oren 1992, Momand et al. 1992, Oliner et al. 1993). Later on, Mdm2 was
shown to function as an E3 ubiquitin ligase that mediates p53 ubiquitination and degradation
(Kubbutat et al. 1997).
The critical role of Mdm2 in the negative regulation of p53 has been shown in vivo.
Homozygous deletion of the mdm2 gene in mice results in embryonic lethality at the blastocyst
stage due to inappropriate apoptosis. Importantly, this phenotype can be rescued by simultaneous
deletion of the p53 gene (Jones et al. 1995, Montes de Oca Luna et al. 1995). Evidently, loss of
MdmX in mice, an Mdm2 homolog, also leads to p53-dependent embryonic lethality, though at a
later stage of development and due to inappropriate proliferation (Finch et al. 2002, Parant et al.
2001). Thus, the balance between p53, Mdm2 and MdmX protein levels is critical in
development and cell survival. Mice with a hypomorphic allele of mdm2, expressing about 30%
of the total Mdm2 level as compared to normal mice, and mice haploinsufficient for mdm2 and
mdmx have decreased body weight, exhibit defects in development and are more radiosensitive
than normal mice (Mendrysa et al. 2003, Terzian et al. 2007). All these phenotypes are p53dependent. Furthermore, in adult mice, Mdm2 is also critical for continuous suppression of the
lethal activity of p53 (Ringshausen et al. 2006).
Regulation of p53 by Mdm2 occurs via a negative feedback loop (Figure 3). The p53
protein binds the mdm2 P2 promoter and transcriptionally up-regulates mdm2 expression (Barak
et al. 1993, Juven et al. 1993, Perry et al. 1993). In turn, the Mdm2 protein, via its E3 ubiquitin
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ligase activity, targets p53 to the proteasome for degradation (Haupt et al. 1997, Honda et al.
1997, Kubbutat et al. 1997). A chain of at least four ubiquitin molecules is believed to be
required for efficient proteasomal degradation (Thrower et al. 2000). Transfection studies show
that Mdm2 promotes the addition of polyubiquitin chains and degradation of p53 when
expressed at high levels and monoubiquitination and nuclear export of p53 when expressed at
low levels (Li et al. 2003). Interestingly, a few groups have shown that Mdm2 mediates a
monomeric ubiquitination of p53 on multiple lysine residues instead of polymeric ubiquitination
(Lai et al. 2001) and the p300 protein, through its E4-like ubiquitin ligase activity, cooperates
with Mdm2 in polyubiquitination of p53 (Grossman et al. 2003, Grossman et al. 1998, Zhu et al.
2001). Mdm2 can also ubiquitinate itself and induce its own degradation (Fang et al. 2000,
Honda and Yasuda 2000).

Figure 3: The p53-Mdm2 auto-regulatory feedback loop. p53 stimulates the expression of
Mdm2. Mdm2 inhibits p53 by blocking its transcriptional activity and also by targeting p53 for
proteasomal degradation. (Adapted from (Chene 2003)).
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Interestingly, there is evidence that the p53 protein can be degraded independently of
Mdm2 (Lee and Gu 2010). Following induction of the p53 protein expression in otherwise p53and Mdm2-null mice the p53 protein levels decrease (Ringshausen et al. 2006), suggesting that a
functional negative feedback loop exists even in the absence of Mdm2. Additional candidates for
regulation of p53 ubiquitination and degradation are Cop1, Pirh2 and ARF-BP1 (Brooks and Gu
2006), Topors (Rajendra et al. 2004), CARPs (Yang et al. 2007) and Synoviolin (Yamasaki et al.
2007). However, the role of these proteins in the regulation of p53 levels has not been confirmed
in vivo. Furthermore, the delay in p53 degradation in the absence of Mdm2 and the subsequent
lethal pathologies indicate that the Mdm2 protein is the key regulator of p53 degradation in vivo
(Marine and Lozano 2010).
In addition to regulating p53 stability, Mdm2 directly inhibits p53-mediated
transactivation by binding to and blocking the p53 transactivation domain (Figure 3) (Momand et
al. 1992, Oliner et al. 1993, Thut et al. 1997, Wu et al. 1993), thus hindering p53 interaction with
transcriptional co-activators (Lin et al. 1994, Thut et al. 1997). In mice with a hypomorphic
allele of mdm2, both transcriptional activation and apoptotic functions of p53 are increased, but
the level of p53 protein does not coordinately increase (Mendrysa et al. 2003). This suggests that
Mdm2 can inhibit the transcriptional activation and apoptotic functions of p53 in a manner
independent of degradation. A chromatin-associated and transcriptionally incompetent p53Mdm2 complex has been detected in cancer cell lines, where Mdm2 localizes to p53-responsive
elements in a p53-dependent manner (Arva et al. 2005, White et al. 2006). These studies show
that when the p53-induced transcription is activated by DNA damage, Mdm2 association with
p53-responsive elements is reduced, suggesting that Mdm2 transiently localizes to p53 target
genes and is released during transactivation. In fact, during p53 activation, acetylation of p53,
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which was shown to be indispensible for p53 activation, blocks the recruitment of Mdm2 to the
p53-responsive promoters thus alleviating Mdm2-mediated transcriptional repression of p53
(Tang et al. 2008).
Interestingly, a recent in vivo study has shown that the Mdm2-p53 interaction, without
Mdm2-mediated p53 ubiquitination, cannot control p53 activity sufficiently. Specifically, mice
with abrogated Mdm2 E3 ubiquitin ligase activity, but retained p53 binding ability, exhibited
p53-dependent embryonic lethality, suggesting that the Mdm2 E3 ubiquitin ligase activity is
required for early mouse embryonic development (Itahana et al. 2007). In fact this particular
study strongly argues that the primary physiological function of Mdm2 is to promote p53
degradation (Clegg et al. 2008). However, a possibility exists that the Mdm2’s E3 ubiquitin
ligase activity is required for ubiquitination of other proteins at the p53-responsive promoters
(Minsky and Oren 2004) or that monoubiquitination rather then polyubiquitination of p53 and or
other proteins by Mdm2 is required for transcriptional repression. In addition, it is also possible
that this particular mutation in the RING domain of Mdm2 (C462A) affects the conformation of
the Mdm2 protein, and therefore, this mutant Mdm2 loses its inhibitory activity towards p53 not
because it has abrogated E3 ubiquitin activity, but because it is conformationally different from
the wild-type Mdm2.
More recently, additional components in the p53-Mdm2 auto-regulatory feedback loop
have been discovered. Mdm2 was shown to inhibit p53 mRNA translation by targeting the L26
ribosomal protein for degradation (Ofir-Rosenfeld et al. 2008, Takagi et al. 2005). Surprisingly,
Mdm2 has also been shown to stimulate p53 mRNA translation by binding directly to the p53
mRNA (Candeias et al. 2008, Naski et al. 2009, Yin et al. 2002). Furthermore, such interaction
of Mdm2 with p53 mRNA suppressed Mdm2’s capacity to promote p53 ubiquitination, leading
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to p53 protein accumulation. These new findings add to the complexity of the p53-Mdm2 autoregulatory feedback loop and suggest that Mdm2 may harbor a dual function towards p53.
Different stress signals lead to disruption of the p53-Mdm2 interaction which allows for
p53 activation and consequent cellular responses. The protein levels of p53 and its negative
regulator Mdm2 normally oscillate in response to a stress signal, which in turn may allow cells to
repair their DNA without risking the irreversible consequences of continuous p53 activation
(Lahav 2008, Lev Bar-Or et al. 2000). DNA damage induces phosphorylation and acetylation of
p53, thus disrupting p53 interaction with Mdm2 and activating p53 transcriptional activity
(Kruse and Gu 2009, Vousden and Prives 2009). Recently, it has been shown that acetylation is
indispensible for p53 activation, as it abrogates Mdm2-mediated repression of p53 by blocking
Mdm2 recruitment to p53-responsive promoters, which in turn leads to p53 activation
independent of its phosphorylation status (Tang et al. 2008). Mdm2 has also been shown to be
phosphorylated after DNA damage and thus lose its E3 ubiquitin activity towards p53 (Cheng
and Chen 2010, Cheng et al. 2009). Interestingly, several studies imply that the p53 posttranslational modifications are not required for p53 function. Disruption of the p53-Mdm2
complex by small molecule inhibitors (e.g. Nutlin-3) is sufficient for p53 pathway activation
(Thompson et al. 2004, Vassilev et al. 2004). Mdm2 knockdown also activates the p53 pathway
without inducing p53 phosphorylation or acetylation of key p53 residues (Giono and Manfredi
2007). In addition, a recent study has shown that while the p53 protein levels transiently
increase due to benign breaks in DNA that occur during normal cell division, p53 activity during
these bursts is kept in check by methylation of several lysine residues at the p53 C terminus
(Berger 2010, Loewer et al. 2010). However, the role of Mdm2 in endogenous regulation of p53
under these conditions has not been examined.
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1.2.3 Mdm2 over-expression inhibits p53 activity
The involvement of Mdm2 in the p53 pathway alludes to the reason for Mdm2’s
transformation potential. Consistent with the in vivo evidence that Mdm2 is indispensable for
p53 activity inhibition (Jones et al. 1995, Montes de Oca Luna et al. 1995), Mdm2 overexpression often occurs in human tumors that retain a wild-type p53 genotype (Landers et al.
1994, Momand et al. 1998). Mdm2 over-expression can occur due to gene amplification (Oliner
et al. 1992, Reifenberger et al. 1993), gene rearrangements (Leach et al. 1993), enhanced
translation (He et al. 1994, Landers et al. 1994), and increased transcription due to a naturally
occurring single nucleotide polymorphism at position 309 (SNP309) in the mdm2 gene P2
promoter (Bond JL et al. 2004, Sheikh et al. 1993).

1.3 p53-independent function of Mdm2 in cell cycle regulation and cell proliferation
Mdm2 over-expression has been shown to be associated with altered cell cycle regulation
(Bouska and Eischen 2009). Mdm2 over-expression drives cell cycle progression and increases
the percentage of cells in the S phase of the cell cycle (Lundgren et al. 1997). This suggests that
Mdm2 over-expression can induce cell cycle progression and thereby increase the likelihood of
passing on mutations that were not corrected during the G1 checkpoint. In part, this increased
proliferation is due to p53 inhibition by Mdm2. However, Mdm2 has also been shown to interact,
independently of p53, with p21, Rb and E2F proteins, which are involved in the G1 to S
transition (Figure 4).
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Figure 4: Mdm2 regulates cell cycle transition through
the G1 checkpoint. Mdm2 forces cells into the S phase by
activating E2F and by facilitating Rb and p21
proteasomal degradation. Adapted from (Bouska and
Eischen 2009).

The p21 cyclin-dependent kinase inhibitor is a cell-cycle regulator that inhibits the G1 to
S phase transition. Since p21 is a transcriptional target of p53 (el-Deiry et al. 1993), Mdm2 can
inhibit p21 expression through its negative regulation of p53. In addition, Mdm2 has been shown
to regulate p21 independently of p53. In cells lacking p53, Mdm2 over-expression results in
decreased p21 protein level, whereas Mdm2 knockdown increases p21 and decreases
proliferation. This occurs by Mdm2 binding to p21, inducing a conformational change in p21 and
thus increasing p21’s interaction with the C8 proteasome subunit (Jin et al. 2003, Xu et al. 2010,
Zhang Z. et al. 2004b).
Mdm2 has been shown to promote cell cycle progression by simultaneously inducing
E2F activity and inhibiting Rb (Figure 4). Hypo-phosphorylated Rb binds and inhibits E2F, a
transcription factor that controls genes necessary for G1 to S cell cycle progression, thus
inducing a G1 arrest (Mundle and Saberwal 2003). Rb phosphorylation by cyclin-dependent
kinases promotes Rb-E2F dissociation, thereby promoting the transcriptional activation of E2F
target genes (Mundle and Saberwal 2003). Mdm2 induces E2F transcriptional activation and thus
cell cycle progression (Martin et al. 1995). Mdm2 has also been shown to regulate the Rb protein
stability through two mechanisms: Mdm2 ubiquitinates Rb (Uchida et al. 2005), and
11

independently of its ubiquitin ligase activity, Mdm2 directly promotes Rb association with the
C8 proteasome subunit (Sdek et al. 2005), thus targeting Rb for proteasomal degradation.

1.4 The role of Mdm2 in breast cancer
1.4.1 Estrogen plays a major role in breast cancers
Estrogen is important in growth and differentiation of normal mammary gland (Gruber et
al. 2002), and also plays a major role in the onset and progression of breast cancers (Pike et al.
1993, Platet et al. 2004). Anti-estrogen endocrine therapy is the therapy of choice for the
majority of women with breast cancers (Jordan and Brodie 2007). Estrogen acts via its receptors
(estrogen receptors: ERα and ERβ), which belong to the nuclear receptor superfamily of ligandactivated transcription factors and control physiological and pathological processes largely by
regulating gene transcription (McDonnell and Norris 2002, Pearce and Jordan 2004). ERα is
believed to be the predominant target of estrogen in breast tissue (Anderson et al. 2002, Fuqua et
al. 2003). About 2/3 of human breast tumors have high ERα levels (Clark et al. 1984) and
depend on estrogen for growth (Beckmann et al. 1997). The mitogenic effects of estrogen are
largely attributed to its ability to increase the expression of key cell-cycle and survival regulatory
genes in hormone responsive tissues, eventually leading to tumor progression (Prall et al. 1997,
Sommer and Fuqua 2001). For example, estrogen induces expression of the anti-apoptotic gene
bcl-2 thus inhibiting apoptosis (Perillo et al. 2000) and also stimulates Myc expression to aid in
cell survival (Rodrik et al. 2006).
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1.4.2 Mdm2 over-expression contributes to tumorigenesis in breast tissue
Mdm2 mRNA and protein over-expression has been observed in breast cancers (BuesoRamos et al. 1996, Meek and Knippschild 2003). Transgenic mice with mdm2 gene expression
specifically in the mammary gland develop mammary tumors, suggesting that over-production of
Mdm2 contributes to tumorigenesis in breast tissue (Lundgren et al. 1997). Evaluation of the
relationship between Mdm2 protein expression and survival in patients with breast carcinoma
shows that patients with Mdm2-positive tumors have worse survival than patients with Mdm2negative tumors (Turbin et al. 2006).

1.4.3 Mdm2 is over-expressed in estrogen receptor α positive breast cancers
Mdm2 appears to be over-expressed in ERα positive (ERα+) human breast cancers (Hori
et al. 2002, Marchetti et al. 1995). ERα+ breast cancer cell lines also exhibit higher expression of
Mdm2 mRNA and protein levels as compared to ERα negative cell lines (Gudas et al. 1995,
Sheikh et al. 1993).
In addition to containing high basal levels of Mdm2 mRNA and protein, ERα+ breast
cancer cell lines show increased Mdm2 expression in the presence of estrogen (Saji et al. 1999).
Estrogen promotes recruitment of ERα to the mdm2 P2 promoter, suggesting a role for ERα in
the regulation of mdm2 gene expression (Kinyamu and Archer 2003). High Mdm2 protein
expression correlates with an increased level of transcription from the mdm2 gene P2 promoter
through binding sites of AP1-ETS family transcription factors and upstream nGGGGC boxes,
but independently of p53 (Okumura et al. 2002b, Phelps et al. 2003).
A single nucleotide polymorphism at position 309 in the mdm2 gene P2 promoter region
(SNP309 T to G) leads to Mdm2 over-expression (Bond JL et al. 2004) and correlates with
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accelerated tumor formation in a gender-specific and estrogen-dependent manner (Bond G. L.
and Levine 2007, Bond G. L. et al. 2006). Because the SNP309 G nucleotide increases SP1
transcriptional co-activator binding affinity and SP1 is a co-activator of ERα, it could potentially
augment the transcriptional regulation of Mdm2 by estrogen. Evidently, estrogen treatment
preferentially stimulates RNA polymerase II loading to the SNP309 G allele of the mdm2 gene,
and preferentially increases Mdm2 protein levels in SNP309 G/G cells (T47-D), intermediately
in SNP309 T/G cells (MCF7), and only marginally in SNP309 T/T cells (ZR75-1) (Hu et al.
2007).

1.4.4 Mdm2 modulates estrogen receptor α function
Mdm2 has been shown to regulate ERα. In the presence of estrogen, Mdm2 overexpressing MCF-7 cells show increased proliferation and increased in vitro transcriptional
activity of ERα (Saji et al. 2001). Furthermore, Mdm2 has been shown to interact directly with
the ERα in a ternary complex with p53 and to be involved in ERα degradation (Duong et al.
2007).

1.5 The role of p53 in breast cancer
The p53 gene is the most commonly mutated gene in human cancers (Vogelstein et al.
2000). Resistance to chemotherapy in breast cancers correlates with the presence of inactivating
mutations in the p53 gene (Berns et al. 2000, Geisler et al. 2001). However, p53 mutations in
breast cancers occur in only 20-30% of the cases (Caleffi M 1994, Coles et al. 1992, Hartmann et
al. 1997, Pharoah et al. 1999). And in fact, the occurrence of p53 mutations in breast cancers is a
late event and is found primarily in ERα negative (ERα-) tumors (Caleffi M 1994, Hartmann et

14

al. 1997). This suggests that in breast cancers p53 activity is suppressed primarily through the
estrogen signaling pathway and/or through the negative regulators of p53.

1.5.1 Estrogen receptor α inhibits p53 activity
ERα can inhibit p53 transcriptional activity by directly interacting with the p53 protein on
the chromatin (Konduri et al. 2010, Liu G. et al. 2000, Sayeed et al. 2007). In MCF-7 breast
cancer xenografts, radiation disrupts the p53-ERα interaction and increases p53-mediated
transcriptional activity (Liu W. et al. 2009). Estrogen has also been shown to affect the posttranslational modifications of p53. In MCF-7 breast cancer cells, estrogen inhibits resveratrolinduced phosphorylation and acetylation of p53, decreases p53-DNA binding and inhibits
apoptosis (Zhang S. et al. 2004a).
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CHAPTER 2:
MATERIALS AND METHODS

16

Cell culture
MCF-7, ZR75-1 and MCF10A normal immortalized mammary epithelial cell lines were obtained
from the American Type Culture Collection (ATCC). MCF-7 and ZR75-1 cells were grown in
RPMI 1640 medium (Mediatech), 10% FBS (Gemini) and 2,500 units of penicillin-streptomycin
(Mediatech) at 5% CO2 370C humidified incubator. MCF10A cells were grown in a 1:1 mixture
of DMEM and Ham’s F-12 medium (Mediatech) containing 0.1 μg/ml cholera enterotoxin, 10
μg/ml insulin, 0.5 μg/ml hydrocortisol, 20 ng/ml epidermal growth factor, 5% horse serum and
2,500 units of penicillin-streptomycin at 5% CO2 370C humidified incubator.

Cloning of mdm2 and p53 shRNA constructs
pSM2c vectors with six different shRNAs for mdm2, four different shRNAs for mdmx, and three
different shRNAs for p53 (see Table 1 below) were cloned into a doxycycline-inducible vector,
STGM PGK PURO (see Figure 5). An empty STGM PGK PURO vector was used as a control.
Reverse tetracycline transcriptional activator (rtTA) expressing plasmid was used to induce
shRNA expression in the presence of doxycycline from the STGM PGK PURO vector in tissue
culture experiments. Vectors were a generous gift from Scott Lowe and Agustin Chicas.

Figure 5: Map of doxycycline-inducible construct for shRNA expression. shRNA oligos for
mdm2, mdmx or p53 were inserted between XhoI and EcoRI restriction sites. GFP expression
was used to assess shRNA expression.
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Table 1: mdm2, mdmx and p53 shRNA sequences.
Clone ID

Position

shRNA sequence

mdm2
254930
151656
254556
262120
151657
254553

802…820
1793…1811
573…591
1924...1942
1836...1854
484...502

CAATTAGTGAGACAGAAGA
CTGTCTATAAGAGAATTAT
GTGCCAAGCTTCTCTGTGA
CCTACTTTGGTAGTGGAAT
GAATTTAGACAACCTGAAA
GCCAGTATATTATGACTAA

mdmx
11941
13023
196120
151660

278…296
246…264
247…265
1097...1115

CTATTTAGGTCAGTACATA
GGTGAAATGTTCACTGTTA
GTGAAATGTTCACTGTTAA
GAAGGATTGGTATTCAGAT

p53
825
1018
2120

825…844
1018…1039
2120…2139

GCATCTTATCCGAGTGGAA
CCGGCGCACAGAGGAAGAGAA
GAGGATTTCATCTCTTGTA

Generation of MCF-7 clonal cell lines containing inducible shRNAs
rtTA plasmid and STGM PGK PURO plasmid (containing shRNA for mdm2, mdmx, or p53)
were introduced into the MCF-7 cells by retrovirus-mediated gene transfer method. Briefly,
Phoenix packaging cells were transfected by calcium phosphate method with either the rtTA
plasmid or with the STGM PGK PURO plasmid. Medium containing the generated viruses was
harvested and MCF-7 cells were co-infected with the two plasmids. After selection with
puromycin (STGM PGK PURO) and hygromycin (rtTA), clonal MCF-7 cell lines were
generated by limited dilution method. During and after infections, MCF-7 cells were grown in
DMEM medium supplemented with 10% FBS (Gemini) and 2,500 units of penicillinstreptomycin. Clonal cell lines were selected based on the level of protein knockdown and GFP
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fluorescence. To induce shRNA expression, cells were treated with 2 µg/ml doxycycline for six
days or as indicated in the figures.

Treatments
Estrogen (17β-estradiol, E2), Etoposide (ETOP), Nutlin-3 (NUT) and DMSO were purchased
from Sigma. 24 hours prior to treatments, growth medium was changed to phenol-red-free RPMI
1640 (Invitrogen) containing 10% charcoal-stripped FBS (Gemini) and antibiotics.

Fresh

medium was supplemented every 72 hours. All estrogen treatments were carried out in RPMI
medium.

Quantitative reverse transcription-PCR (qRT-PCR)
RNA was isolated using QIAshredder columns and RNeasy Mini Kit (Qiagen). 5 µg of RNA
was used for cDNA synthesis using High Capacity cDNA Archive Kit reagents (Applied
Biosystems). 150 ng of cDNA was combined with Taqman Universal Master Mix and Applied
Biosystems Assays on Demand primers/probes for puma (Hs00248075_m1), mdm2
(Hs00242813_m1), p21 (Hs00355782_m1) and actin (4352935E). PCR reaction was carried out
in 7500 Sequence Detection System (Applied Biosystems). P-values were calculated by student
t-test.

Whole cell protein extract
Cells were harvested and washed in 1xPBS. Cells were lysed in RIPA buffer (0.1% SDS, 1%
NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Tris-Cl pH8,
1 mM PMSF, 8.5 μg/ml Aprotinin and 2 μg/ml Leupeptin) following standard protocol.
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Histone protein extract
Cells were harvested and washed in 1xPBS. Cells were resuspended in Triton Extraction Buffer
(TEB) at cell density of 107 cells/ml (4 ml for 150 mm plate of cells). TEB recipe: in 50 ml PBS:
0.5 % v/v Triton X 100, 2 mM PMSF and 0.02% w/v NaN3. Cells were lysed on ice for 10 min
with gentle stirring, followed by centrifugation for 10 min at 1200 rpm 40C. The pellets were
washed in half the volume of TEB and centrifuge for 10 min at 1200 rpm 40C. Pellets were
resuspended in 0.2 N HCl at a cells density of 4x107 cells/ml (~100-200 µl). Acid extraction was
done by rocking the samples 40C overnight, followed by centrifugation for 10 min at 2000 rpm
40C to rid of cell debry.

Western blot
50 µg of protein extract were separated by 10% SDS-PAGE and electro-transferred to
nitrocellulose membrane. Immunoblotting was done with p53 antibodies (pAb421, pAb240 and
pAb1801); Mdm2 (SMP-14 from Santa Cruz sc-965 or from Sigma M4308); ERα (Santa Cruz
HC-20); MdmX (Bethyl laboratories BL1258); Bcl-2 (100 Santa Cruz sc-509); Puma (Cell
Signaling 4976); p21 (Ab-1 Oncogene Research Science OP64); H2AX (Millipore MAB3406);
γH2AX Ser139 (Millipore, 05-636); Actin (Sigma A2066).

Immunofluorescence
Cells, grown and treated on coverslips, were fixed with 4% Formaldehyde and permeabilized
with 0.5% Triton-X-100. Immunohistochemistry was done with p53 (FL-393 Santa Cruz sc6243), Mdm2 (SMP-14 Santa Cruz sc-965) or γH2AX Ser139 (Millipore, 05-636) antibodies
followed by incubation with FITC-conjugated anti-mouse (Jackson ImmunoResearch 715-095-
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150) or Alexa-conjugated anti-rabbit (Invitrogen A11037). Coverslips were mounted onto slides
using Vectashield mounting medium with DAPI (Fisher Scientific NC9524612). Images were
collected by PerkinElmer UltraVIEW ERS Spinning Disc Microscope.

Chromatin immunoprecipitation (ChIP)
Cells were incubated with 1% Formaldehyde for 30 min at 5% CO2 370C humidified incubator,
followed by 0.125 M Glycine treatment for 5 min. Cells were lysed in RIPA buffer (0.1% SDS,
1% NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Tris-Cl
pH8, 1 mM PMSF, 8.5 μg/ml Aprotinin, 2 μg/ml Leupeptin and Phosphatase Inhibitor Cocktail 1
(Sigma)). Lysates were sonicated 10 times (1 min pulse and 1 min rest) in a Branson Digital
Sonifier and spun down for 30 min 13,000 rpm at 40C. 400 µg of cell lysates were subjected to
overnight incubation at 40C with 2 µg of p53 (Ab-6 Calbiochem OP43); Mdm2 (N-20 Santa
Cruz sc-813); RNA polymerase II (RNAPII H-224 Santa Cruz sc-9001) or non-specific IgG
(Santa Cruz, IgG mouse sc-2025, IgG rabbit sc-2027). 50 µl of 25% beads slurry of protein A/G
Plus Agarose beads (Santa Cruz sc-2003), pre-blocked with 0.3 mg/ml sheared herring sperm
DNA (Invitrogen, 15634-017), were added to immunoprecipitation samples for 2 hours at 40C,
followed by washes: (1) 0.1% SDS, 1% Triton-X-100, 20 mM Tris pH8.1, 150 mM NaCl; (2)
0.1% SDS, 1% Triton-X-100, 20 mM Tris pH8.1, 500 mM NaCl; (3) 0.25 M LiCl, 1% NP-40,
1% Deoxycholate, 1 mM EDTA, 10 mM Tris pH8; and (4) twice with TE pH8.
Immunoprecipitated chromatin was de-crosslinked overnight at 650C with 1 mg/ml ProteinaseK,
1% SDS and 0.1M NaHCO3. For total DNA input, 40 µg were similarly de-crosslinked. DNA
fragments were purified using Qiagen QiaQuick kit (Qiagen) and amplified by real-time
quantitative PCR in 7500 Sequence Detection System (Applied Biosystems). The primers and
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probes sequences for p53 responsive elements (p53-REs) in puma, mdm2 and p21 were based on
(Kaeser and Iggo 2002). Same primers were used for TATA box regions in puma and mdm2
genes because of the close proximity. p21 TATA box primers were based on (Gomes et al.
2006). See table 2 below. P-values were calculated by student t-test.

Table 2: Primers used in chromatin immunoprecipitation.

puma p53-REs and TATA box

mdm2 p53-REs and TATA box

p21 p53-Res
p21 TATA box

forward primer: GCGAGACTGTGGCCTTGTGT
reverse primer: CGTTCCAGGGTCCACAAAGT
probe: TGTGAGTACATCCTCTGGGCTCTGCCTG
forward primer: GGTTGACTCAGCTTTTCCTCTTG
reverse primer: GGAAAATGCATGGTTTAAATAGCC
probe: GCTGGTCAAGTTCAGACACGTTCCGAA
forward primer: GTGGCTCTGATTGGCTTTCTG
reverse primer: CTGAAAACAGGCAGCCCAA
probe: TGGCATAGAAGAGGCTGGTGGCTATTTTG
forward primer: TATATCAGGGCCGCGCTG
reverse primer: GGCTCCACAAGGAACTGACTTC

mdm2 siRNA transfection
Cells were seeded in media with no antibiotics. After 24 hours, 10 µl Lipofectamine2000
(Invitrogen) was incubated for 5 min with 240 µl Optimem (Invitrogen). 0.2 nmol (100 nM) of
non-specific or mdm2 siRNA (Dharmacon) were resuspended in 250 µl Optimem and combined
with Lipofectamine2000. After 20 min, 500 µl siRNA-Lipofectamine2000 mix was added to
cells with 1.5 ml Optimem. Six hours later, 1.5 ml of RPMI growth medium with 20% FBS was
supplemented, to have 10% final FBS concentration. The next day, treatments were carried out
as described in the figures.
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Viability and cell count assay
Viability (cell permeability) and number of cells were determined by the Guava Viacount assay
according to manufacturer’s protocol (Millipore). Graphs show means and standard errors of
three independent experiments. P-values were calculated by student t-test.

MTT assay
Percent of cell proliferation was determined by the MTT assay. After treatments, cells were
incubated

for

1

hour

with

the

MTT

reagent

(3-(4,5-Dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide, a tetrazole). MTT was reduced to formazan by the mitochondrial
reductase enzymes in the cells. Formazan crystals were dissolved in MTT solubility solution,
containing Triton-X-100 and HCl in PBS. Graphs show means and standard errors of three
independent experiments. P-values were calculated by student t-test.

Fluorescence activated cell sorting (FACS)
FACS was performed on a FACScan (BD Biosciences). After treatments, cells were harvested,
washed, resuspended in PBS containing 2% bovine serum albumin and 0.1% sodium azide, fixed
in 30% ethanol, and stored overnight at 40C. Before sorting, propidium iodide staining and
RNase treatment were performed for 30 minutes at 370C. P-values were calculated by student ttest.

Cell culture in matrigel
MCF-7 cells were seeded at a density of 5x103 cells per cm2 on top of 50 µl solidified matrigel
(BD Biosciences) in MEBM basal medium without phenol red (Lonza CC-3153) supplemented

23

with bullet kit components except for BPE (Lonza CC-4156), 10% charcoal FBS and 2%
matrigel, in the presence of 10 nM estrogen and in the absence or presence of 2 μg/ml
doxycycline. Medium was changed every three days. Brightfield pictures show mass structures
that MCF-7 cells form in matrigel after 3 weeks. MCF-7 cells were also fixed directly in culture
with 4% Formaldehyde and stained with propidium iodide. Confocal analysis was performed
using Laser scanning spectral confocal microscope TCS SP2. Large, intermediate and small mass
structures were counted and presented as percent of the total population. P-values were
calculated by student t-test.

Colony formation in soft agar
5,000 MCF-7 cells were mixed with 0.3% Nobel agar (Sigma A5431) in growth medium, 10 nM
estrogen, and with or without 2 µg/ml doxycycline. Cells were seeded onto 35 mm dishes coated
with 0.5% Nobel agar in growth medium. Cells were then fed with the growth medium, estrogen,
and with or without doxycycline. Plates were incubated at 5% CO2 370C humidified incubator
for 14 days. Culture medium was replaced every three days. Colonies were fixed in 4%
formaldehyde, stained with 0.005% crystal violet and counted under dissecting microscope.
Images were collected by inverted phase and fluorescent microscope. P-values were calculated
by student t-test.
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CHAPTER 3:
RESULTS
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3.1 Examining the effects of estrogen-mediated Mdm2 over-expression on the p53 pathway.
3.1.1 Introduction
A majority of estrogen receptor α positive (ERα+) breast cancers carries a wild-type p53
gene (Hartmann et al. 1997, Pharoah et al. 1999). Therefore, understanding how p53 is inhibited
and restoring its function are relevant issues in the breast cancer therapy field. p53 plays a central
role in cell cycle arrest, DNA repair and apoptosis pathways (Vogelstein et al. 2000). In contrast,
ERα positively regulates growth and development of various tissues, and promotes increased
proliferation of breast cancer cells in the presence of estrogen (Pearce and Jordan 2004). ERα
over-expression in breast cancers has been shown to correlate with high expression of the Mdm2
oncogene (Gudas et al. 1995, Hori et al. 2002, Sheikh et al. 1993). Since Mdm2 is a major
negative regulator of p53, it is possible that in the ERα+ breast cancers that over-express Mdm2,
the delicate balance between the opposing functions of the p53-mediated tumor suppression and
the ERα-mediated cell proliferation is disrupted.
In this study we examined the role of Mdm2 in the estrogen-mediated breast cancer cells
proliferation. While Mdm2 has been implicated in estrogen’s mechanism of action, the role that
Mdm2 plays in this process has not been clearly defined. Our goal was to determine if in the
ERα+ breast cancer cells, estrogen-mediated cell proliferation depended on Mdm2 and whether
Mdm2 was inhibiting the p53 pathway in this process (see Figure 6).

Figure 6: A model illustrating the fundamental hypothesis of
this study. Since estrogen is known to promote Mdm2 overexpression in breast cancer cells, we hypothesized that the
estrogen-mediated cell proliferation is dependent on Mdm2. Since
Mdm2 is a major negative regulator of p53, we proposed that the
increased cell proliferation in the presence of estrogen occurs
through inhibition of the p53 pathway via Mdm2.
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The experiments were carried out in the MCF-7 and ZR75-1 breast cancer cell lines, two
commonly used breast carcinoma cell lines. Both cell lines have ERα and are considered ERα+
cells and also carry a wild-type p53 (see Table 3). In one allele of the mdm2 gene P2 promoter,
the MCF-7 cells carry a G nucleotide instead of the commonly found T nucleotide (a single
nucleotide polymorphism at position 309 (SNP309 TG)), while the ZR75-1 cells carry two T
alleles. Importantly, the G allele in the mdm2 gene promoter has been shown to lead to Mdm2
over-expression (Bond JL et al. 2004) and to correlate with accelerated tumor formation in a
gender-specific and estrogen-dependent manner (Bond G. L. and Levine 2007, Bond G. L. et al.
2006). Furthermore, estrogen treatment has been shown to up-regulate the Mdm2 protein level
more robustly in the MCF-7 cells (SNP309 T/G) than in the ZR75-1 cells (SNP309 T/T) (Hu et
al. 2007).

Table 3: Breast cancer cell lines used in this study.
Cell lines

ERα

p53

Mdm2
SNP309

MCF-7

+

wild-type

T/G

ZR75-1

+

wild-type

T/T
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3.1.2 Results
A major proliferation and survival advantage is seen in MCF-7 cells treated with estrogen
for five days (Rodrik et al. 2006, Shanmugam et al. 1999). When we treated MCF-7 cells with 10
nM estrogen for five days in otherwise steroids-depleted growth medium, we observed that the
cell proliferation increased by 2.8 fold (Figure 7A). Importantly, the increase in MCF-7 cells
proliferation in the presence of estrogen correlated with a dramatic increase in the Mdm2 protein
level (Figure 7B). This observation served as a ground for our hypothesis that Mdm2 overexpression plays an important role in the estrogen-mediated cell proliferation. Interestingly, we
observed that there were different forms of the Mdm2 protein present in both the untreated and
estrogen treated cells, as the Mdm2 Western blot showed several bands for the Mdm2 protein
(Figure 7B). The different forms of Mdm2 detected in the untreated cells were all up-regulated in
the presence of estrogen (Figure 7B).

Figure 7: Prolonged estrogen treatment increased cell proliferation and the Mdm2 protein
level in the MCF-7 cells. MCF-7 cells were grown in the presence of 10 nM estrogen (E2) for
five days. (A) 10,000 cells were seeded at the beginning of estrogen treatment. Number of cells
after five days was determined by Guava Viacount assay. (B) Mdm2 and Actin protein levels in
whole cell lysates were analyzed by Western blot.
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In the previous experiment (see Figure 7 above), we observed that prolonged estrogen
treatment substantially increased the Mdm2 protein level which correlated with increased MCF-7
cells proliferation. Therefore, we hypothesized that estrogen may also promote an increase in the
Mdm2 protein level in the presence of a stress signal, which in turn would block the p53mediated response to the stess. As a stress signal we used two different drugs: a DNA damaging
agent, etoposide, and also a small molecule Mdm2 inhibitor, Nutlin-3. Etoposide is a cytotoxic
chemotherapeutic agent that causes DNA double strand breaks by interfering with the scissionreunion reaction of the topoisomerase II (van Maanen et al. 1988). Nutlin-3 is a small molecule
cis-imidazoline analog, which inhibits the interaction between the N termini of Mdm2 and p53
by binding to the hydrophobic pocket in the N terminus of Mdm2 (Vassilev et al. 2004).
Initally, we examined the effects of etoposide and Nutlin-3 treatments on MCF-7 cell
proliferation in the presence of a prolonged estrogen treatment. We observed that etoposide
treatment for 48 hours in the presence of estrogen increased the percent of cells in the G2/M
phase of the cell cycle and concomitantly decreased the percent of cells in the G1 phase (Figure
8A, etoposide). In turn, Nutlin-3 treatment for 24 hours in the presence of estrogen increased the
percent of cells in the G1 phase and decreased the percent of cells in the S phase (Figure 8A,
Nutlin-3). This suggests that etoposide treatment caused the cells to slow down at the G2/M
checkpoint transition, while Nutlin-3 treatment caused a G1 arrest-like state. The 24 hours of
Nutlin-3 treatment inhibited cell proliferation to a lesser extent than the 48 hours of etoposide
treatment (Figure 8B), probably because of the difference in the duration of the treatments.
However, further studies are needed to determine that for sure. In future studies it will be
important to determine the IC50 (Inhibitory Concentration) for etoposide and Nutlin-3 drugs
(time curves and drug concentration curves). Also, a BrdU incorporation assay (BrdU is a
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synthetic thymidine analog) is needed to determine if the cells are completely arrested after the
treatments or just slow down in their transition through the cell cycle checkpoints. Lack of BrdU
incorporation after etoposide or Nutlin-3 treatments would indicate that the drugs induced an
arrest at the corresponding phases of the cell cycle.
In conclusion, we observed that in the MCF-7 cells, etoposide and Nutlin-3 treatments in
the presence of estrogen increased the percent of cell populations in the G2/M and G1 cell cycle
phases respectively (Figure 8A) and moderately decreased cell proliferation (Figure 8B) without
affecting the cellular membrane integrity, as measured by the cell viability assay (Figure 8C).
This suggests that the drugs, at the conditions used, inhibited cell proliferation and did not induce
cell death. In all the subsequent experiments, unless otherwise indicated, the above conditions
were used for etoposide and Nutlin-3 treatments.
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Figure 8: In MCF-7 cells, etoposide and Nutlin-3 treatments in the presence of estrogen
increased the percentage of cells in the G2/M and G1 cell cycle phases respectively and
moderately decreased cell proliferation. MCF-7 cells were treated with 10 nM estrogen (E2) for
five days, 50 μM etoposide (ETOP) for 48 hours and 10 μM Nutlin-3 (NUT) for 24 hours. (A)
Cell cycle phases were determined by fluorescence activated cell sorting (FACS). (B) Number of
cells and (C) cell viability based on membrane permeability were determined by Guava Viacount
assay at the end of the treatments.
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Because etoposide and Nutlin-3 treatments in the presence of estrogen inhibited MCF-7
cells proliferation only moderately, we wanted to determine if such an ineffective response to the
drugs correlated with increased Mdm2 protein expression. Drug treatments alone (etoposide or
Nutlin-3) increased the protein level of Mdm2 (Figure 9, compare lanes 1-3-5). Mdm2 is a p53
target gene. Therefore, the drug-induced increase in the Mdm2 protein level was probably due to
activation of the p53 transcriptional activity by these drugs (see more on this in Figure 11
below). Importantly, we observed that similarly to increasing the basal protein level of Mdm2,
prolonged estrogen treatment further up-regulated the Mdm2 protein level after both etoposide
and Nutlin-3 treatments (Figure 9, compare lanes 1-2, 3-4, 5-6).
In addition, we also examined if estrogen had any effect on the p53 protein expression.
Since one of the major functions of Mdm2 is to promote p53 ubiquitination and subsequent
proteasomal degradation, we hypothesized that in the presence of estrogen the increased Mdm2
protein level would lead to a decrease in the p53 protein level. However, it was surprising to see
that while estrogen increased the Mdm2 protein level, the p53 protein level did not decrease, but
in fact increased as well (Figure 9, compare lanes 1-2).
To determine if estrogen influenced the p53 protein level after a drug treatment, we
treated the cells with etoposide or Nutlin-3 in the absence and in the presence of estrogen. DNA
damage induced by etoposide treatment increased the p53 protein level (Figure 9, compare lanes
1-3), while estrogen treatment caused no significant change (Figure 9, compare lanes 3-4).
Similarly, the p53 protein level increased dramatically after Nutlin-3 treatment (Figure 9,
compare lanes 1-5) while estrogen had no effect (Figure 9, compare lanes 5-6).
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In conclusion, we observed that in the MCF-7 breast cancer cells estrogen-mediated upregulation of basal and drug-induced Mdm2 protein levels did not lead to p53 protein downregulation.

Figure 9: In MCF-7 cells, prolonged estrogen treatment increased the basal and the druginduced Mdm2 protein levels, but did not down-regulate the p53 protein levels. MCF-7 cells
were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48 hours and
10 μM Nutlin-3 (NUT) for 24 hours. Mdm2, p53 and Actin protein levels of whole cell lysates
from MCF-7 cells were analyzed by Western blot. Lower strip of Mdm2 shows a lighter
exposure.
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Importantly, in a recently published study a comparison of the Mdm2 protein expression
in the MCF-7 and the ZR75-1 breast cancer cells in the presence of estrogen showed that
estrogen treatment robustly increased the Mdm2 protein level in the MCF-7 cells, but not in the
ZR75-1 cells (Hu et al. 2007). This work showed that the increase in the Mdm2 protein
expression was mediated by the SNP309 G allele in the mdm2 gene promoter. As mentioned
earlier, the MCF-7 cells are SNP309 heterozygous T/G, while the ZR75-1 cells are SNP309
homozygous T/T. To follow up on our observations in the MCF-7 cells (see Figure 9 above), we
also examined the effect of prolonged estrogen treatment on the Mdm2 protein expression in the
ZR75-1 cells. Importantly, similarly to Hu et al. findings, we observed that estrogen treatment
did not increase the Mdm2 protein level in the ZR75-1 cells (Figure 10, compare lanes 1-2) as it
did in the MCF-7 cells (see Figure 9 above, compare lanes 1-2).
In addition to examining the effect of prolonged estrogen treatment on the basal Mdm2
protein expression in the ZR75-1 cells, we also carried out experiments to determine if estrogen
had any effect on the Mdm2 protein expression in the presence of a drug treatment. Interestingly,
in contrast to the MCF-7 cells, where etoposide treatment increased the Mdm2 protein level (see
Figure 9 above, compare lanes 1-3), in ZR75-1 cells etoposide treatment decreased the Mdm2
protein level (Figure 10, compare lanes 1-3). Importantly, similar to the fact that estrogen did not
affect the basal level of the Mdm2 protein in the ZR75-1 cells (Figure 10, compare lanes 1-2),
estrogen addition to the etoposide treatment also had no effect on the Mdm2 protein level (Figure
10, compare lanes 3-4). Likewise, while Nutlin-3 treatment dramatically increased the Mdm2
protein level in the ZR75-1 cells (Figure 10, compare lanes 1-5), estrogen addition to the Nutlin3 treatment had no effect on the Mdm2 protein level (Figure 10, compare lanes 5-6).
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It is not clear why in contrast to the MCF-7 cells, where etoposide treatment increased the
Mdm2 protein level, etoposide treatment decreased the Mdm2 protein level in the ZR75-1 cells.
Activation of kinases (e.g. ATM and ATR) by DNA damage is known to induce Mdm2 autodegradation (Stommel and Wahl 2004) and this is probably what we observed in the ZR75-1
cells. In turn, it is possible that in the MCF-7 cells, this pathway is compromised and therefore
the Mdm2 protein was not degraded after DNA damage in these cells. In addition, a major
difference between the MCF-7 and ZR75-1 cell lines with respect to the Mdm2 protein
regulation is that the MCF-7 cells carry a homozygous deletion for the ink4a/arf gene (Ikediobi
et al. 2006, Musgrove et al. 1995). The Ink4a/ARF protein binds to Mdm2, sequesters it to the
nucleolus (Weber et al. 1999) and also promotes Mdm2 degradation (Zhang Y. et al. 1998).
Therefore, it is possible that DNA damage (induced by etoposide) activated the Ink4a/ARF
pathway in the ZR75-1 cells but not in the MCF-7 cells, which, in turn, led to Mdm2 degradation
in the ZR75-1 cells but not in the MCF-7 cells. It is not known, however, if the Ink4a/ARF
expression is regulated by DNA damage.
We also examined if estrogen had any effect on the p53 protein expression in the absence
and in the presence of a drug treatment. Prolonged estrogen treatment appeared to have no effect
on the basal p53 protein level in the ZR75-1 cells (Figure 10, compare lanes 1-2). As expected,
DNA damage induced by etoposide treatment led to an increase in the p53 protein level (Figure
10, compare lanes 1-3), while estrogen had no effect (Figure 10, compare lanes 3-4). And
likewise, Nutlin-3 treatment increased the p53 protein level dramatically (Figure 10, compare
lanes 1-5), while estrogen had no effect (Figure 10, compare lanes 5-6).
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In conclusion, we observed that similarly to the previously published findings (Hu et al.
2007), in the ZR75-1 cells estrogen did not up-regulate the Mdm2 protein expression as it
robustly did in the MCF-7 cells. And in addition, we found that in the presence of a stress signal,
such as DNA damage or p53 activation by a small molecule inhibitor, estrogen also had no effect
on the Mdm2 protein levels in the ZR75-1 cells while it up-regulated the Mdm2 protein
expression in the MCF-7 cells.

Figure 10: In ZR75-1 cells, prolonged estrogen treatment did not affect the Mdm2 and p53
protein levels. ZR75-1 cells were treated with 10 nM estrogen (E2) for five days, 50 μM
etoposide (ETOP) for 48 hours and 10 μM Nutlin-3 (NUT) for 24 hours. Mdm2, p53 and Actin
protein levels of whole cell lysates from ZR75-1 cells were analyzed by Western blot. Lower strip
of Mdm2 shows a lighter exposure.
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Mdm2 is a major negative regulator of p53. We observed that in the MCF-7 breast cancer
cells prolonged estrogen treatment increased both the basal and the drug-induced Mdm2 protein
levels. However, though the Mdm2 expression was up-regulated in the presence of estrogen, the
p53 protein stability was sustained. Therefore, we hypothesized that perhaps the increased Mdm2
protein expression affected the p53 protein transcriptional activity without affecting the p53
protein stability.
To examine the effect of prolonged estrogen treatment on the p53 transcriptional activity
in the MCF-7 cells, we looked at the effect of estrogen treatment on etoposide- and Nutlin-3mediated fold activation of three different p53 target genes: puma (involved in apoptosis), mdm2
(involved in negative regulation of p53) and p21 (involved in cell cycle arrest). We observed that
the basal expression of the p53 target genes puma and p21 was significantly down-regulated after
prolonged estrogen treatment (Figure 11, compare black and gray bars in DMSO samples).
Furthermore, while, as expected, etoposide and Nutlin-3 treatments up-regulated the expression
of all three p53 target genes that we examined (Figure 11, compare black bars between DMSO,
etoposide and Nutlin-3 samples), p53 target genes expression was differently affected when
estrogen was added to the treatments (Figure 11, compare black and gray bars). Specifically,
estrogen inhibited etoposide- and Nutlin-3-induced puma transactivation, but not that of the
mdm2 and p21 genes (Figure 11, compare black and gray bars).
In conclusion, we observed that in the MCF-7 cells prolonged estrogen treatment robustly
inhibited basal and drug-induced expressions of the pro-apoptotic p53 target gene puma.
Additionally, estrogen robustly inhibited the basal expression of a growth-arrest p53 target gene
p21, but had no effect on its expression in the presence of the stress-inducing stimuli.
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Figure 11: In MCF-7 cells, prolonged estrogen treatment inhibited basal expressions of puma
and p21 genes and also inhibited etoposide- and Nutlin-3-mediated expression of puma. MCF7 cells were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48
hours and 10 μM Nutlin-3 (NUT) for 24 hours. Relative levels of puma, mdm2 and p21 mRNA
transcripts were determined by quantitative real-time RT-PCR. Values were normalized to
DMSO samples and actin levels. Graphs show means and standard errors of two independent
experiments. * p < 0.05 (determined by student t-test).
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Because we observed that in the MCF-7 cells estrogen robustly inhibited the basal and
the drug-induced expressions of the pro-apoptotic p53 target gene puma, we wanted to determine
if this inhibition in transcription was functionally important. Therefore, in addition to examining
the mRNA levels of puma, we also carried out Western blot experiments to determine if estrogen
affected the protein levels of Puma as well. In direct correspondence with the transcription data,
where estrogen decreased both the basal and the drug-induced puma mRNA expression, we
observed that prolonged estrogen treatment in the absence and in the presence of etoposide and
Nutlin-3 treatments decreased the protein levels of Puma (Figure 12, compare lanes 1-2, 3-4, 56).
Importantly, the pro-apoptotic protein Puma plays a major role in apoptosis induction by
negatively regulating the anti-apoptotic protein Bcl-2 (Yu and Zhang 2009). In turn, the bcl-2
gene is an ERα target gene and estrogen has been shown to inhibit apoptosis by inducing the bcl2 gene expression in the MCF-7 cells (Perillo et al. 2000). Therefore, in addition to examining
the effect of prolonged estrogen treatment on the Puma protein expression we also examined
how estrogen affected the Bcl-2 protein expression in the MCF-7 cells. We observed that
prolonged estrogen treatment both in the absence and in the presence of etoposide and Nutlin-3
treatments increased the protein levels of Bcl-2 (Figure 12, compare lanes 1-2, 3-4, 5-6).
In conclusion, we observed that in the MCF-7 breast cancer cells, prolonged estrogen
treatment, both in the absence and in the presence of etoposide and Nutlin-3 drugs, coordinately
decreased the pro-apoptotic Puma protein levels while increasing the anti-apoptotic Bcl-2 protein
levels. This observation suggests that in the MCF-7 breast cancer cells estrogen signals towards
the anti-apoptotic pathway by decreasing Puma and by simultaneously increasing Bcl-2, and thus
increases cell survival during induced proliferation.
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Figure 12: In MCF-7 cells, prolonged estrogen treatment in the absence and in the presence
of etoposide and Nutlin-3 drugs decreased Puma and increased Bcl-2 protein levels. MCF-7
cells were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48 hours
and 10 μM Nutlin-3 (NUT) for 24 hours. Protein levels of Puma, Bcl-2 and Actin from whole cell
lysates were analyzed by Western blot.
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Because in the ZR75-1 cells prolonged estrogen treatment did not up-regulate the Mdm2
protein expression (basal and drug-induced) as it robustly did in the MCF-7 cells, we
hypothesized that in the ZR75-1 cells the p53 transcriptional activity would not be affected by
the estrogen treatment. Similar to the MCF-7 cells, to examine the effect of prolonged estrogen
treatment on the p53 transcriptional activity in the ZR75-1 cells, we looked at the effect of
estrogen treatment on etoposide- and Nutlin-3-mediated fold activation of three different p53
target genes: puma, mdm2 and p21.
We observed that in the ZR75-1 cells, prolonged estrogen treatment did not decrease the
basal and the etoposide-mediated activation of the three p53 target genes that we examined
(Figure 13, compare black and gray bars in DMSO and etoposide samples). Importantly, this
observation supported our hypothesis. But surprisingly, prolonged estrogen treatment
significantly reduced the Nutlin-3-mediated activation of all three p53 target genes (Figure 13,
compare black and gray bars in Nutlin-3 treatment).
Interestingly, though both cell lines, MCF-7 and ZR75-1, are ERα positive and carry a
wild type p53, estrogen affected differently the p53 transcriptional activity in the two cell lines.
It is possible that since the MCF-7 cells carry the G allele for the SNP309 (TG) and overexpress the Mdm2 protein in the presence of estrogen, the basal expression of puma and p21
mRNA transcripts was inhibited in the MCF-7 cells, but not in the ZR75-1 cells. And similarly,
etoposide-mediated puma induction was inhibited in the MCF-7 cells, but not in the ZR75-1
cells. However, it is not clear why in the ZR75-1 cells estrogen inhibited the Nutlin-3-mediated
expression of all three genes that we examined, while in the MCF-7 cells only puma was
inhibited. Since in the ZR75-1 cells, estrogen treatment did not up-regulate the Mdm2 protein
level, the inhibition of Nutlin-3-induced gene expression in these cells was probably independent
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of Mdm2. It possible, for example, that a wide range of genes (including the p53 target genes) is
affected in the ZR75-1 cells when the Nultin-3 treatment is combined with estrogen.

Figure 13: In ZR75-1 cells, prolonged estrogen treatment did not affect the basal and the
etoposide-mediated puma, mdm2 and p21 genes expression, but inhibited the Nutlin-3mediated expression of all three genes. ZR75-1 cells were treated with 10 nM estrogen (E2) for
five days, 50 μM etoposide (ETOP) for 48 hours and 10 μM Nutlin-3 (NUT) for 24 hours.
Relative levels of puma, mdm2 and p21 mRNA transcripts were determined by quantitative realtime RT-PCR. Values were normalized to DMSO samples and actin levels. Graphs show means
and standard errors of two independent experiments. * p < 0.05 (determined by student t-test).
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Estrogen signaling is mediated primarily through the ERα protein, a nuclear transcription
factor (McDonnell and Norris 2002, Pearce and Jordan 2004). Therefore, in addition to
examining the effect of prolonged estrogen treatment on the p53-Mdm2 pathway in the MCF-7
and ZR75-1 breast cancer cells, we also examined how estrogen affected the ERα protein levels
in these cells. We observed that in both MCF-7 and ZR75-1 cells prolonged estrogen treatment
decreased the ERα protein levels (Figure 14A and 14B, compare lanes 1-2). In the ZR75-1 cells,
however, the estrogen-mediated decrease in the ERα protein level was more robust than in the
MCF-7 cells (Figure 14A and 14B, compare lanes 1-2).
Interestingly, estrogen has been shown to negatively regulate the ERα protein level via
the proteasomal degradation in an Mdm2-dependent manner, where Mdm2 acts as an E3
ubiquitin ligase towards ERα (Duong et al. 2007). We observed that the Mdm2 protein level
increased after estrogen treatment in the MCF-7 cells but not in the ZR75-1 cells. Therefore, if
the estrogen-mediated degradation of the ERα protein was Mdm2-dependent, then one would
expect to see a greater degradation of the ERα protein in the cells that had more Mdm2 (the
MCF-7 cells). But in turn, we observed the opposite. The ZR75-1 cells, that showed no increase
in the Mdm2 protein after estrogen treatment, had lower ERα protein level after estrogen
treatment than the MCF-7 cells (Figure 14A and 14B, compare lanes 1-2). This suggests that the
estrogen-mediated down-regulation of the ERα protein in the MCF-7 and ZR75-1 cells depends
not only on the Mdm2 protein.
In addition, we also examined the ERα protein levels after etoposide and Nutlin-3
treatments in the absence and in the presence of a prolonged estrogen treatment. Similar to the
estrogen treatment, etoposide also decreased the ERα protein levels in both cell lines (Figure
14A and 14B, compare lanes 1-3), and the effect was additive when estrogen and etoposide
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treatments were combined (Figure 14A and 14B, compare lanes 3-4). Nutlin-3 treatment also
slightly reduced the ERα protein levels in both cell lines (Figure 14A and 14B, compare lanes 15), while the addition of estrogen reduced the ERα protein level in the ZR75-1 cells but not in the
MCF-7 cells (Figure 14A and 14B, compare lanes 5-6). Interestingly, it was recently shown that
other agents, such as UV and RITA (a small molecule that inhibits the interaction between p53
and Mdm2 by binding to the p53 protein (Sun et al. 1998)) also affect the estrogen-dependent
ERα turnover (Duong et al. 2007).
In conclusion, our observations suggest that agents that signal to the p53 pathway (e.g.
etoposide and Nutlin-3) also affect the ERα signaling pathway, implicating the existence of a
cross-talk between the two pathways.

Figure 14: Estrogen, etoposide and Nutlin-3 treatments decreased the estrogen receptor α
(ERα) protein levels in both MCF-7 and ZR75-1 cells. MCF-7 and ZR75-1 cells were treated
with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48 hours and 10 μM Nutlin3 (NUT) for 24 hours. Protein levels of ERα and Actin from whole cell lysates of MCF-7 (A) and
ZR75-1 (B) cells were analyzed by Western blot.
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We observed that in the MCF-7 breast cancer cells prolonged estrogen treatment
decreased both the basal and the drug-induced expression of the p53 target gene puma while the
p53 protein levels did not decrease. Therefore, we hypothesized that the estrogen-mediated
inhibition of puma expression might have been due to nuclear exclusion of the p53 protein after
estrogen treatment. In fact, nuclear exclusion of p53 has been shown to occur following estrogen
treatment in the breast cancer cells (Molinari et al. 2000, Moll et al. 1992). We, therefore,
evaluated by immunofluorescent staining if the nuclear exclusion of p53 could explain the
estrogen-mediated inhibition of puma mRNA expression in the MCF-7 cells.
When we examined how prolonged estrogen treatment affected the cellular localization
of the p53 protein in the MCF-7 cells, we observed that estrogen treatment did not lead to a
nuclear exclusion of the p53 protein (Figure 15A, DMSO treatment). And in fact, it appeared that
estrogen treatment moderately increased the nuclear localization of the p53 protein (Figure 15A,
DMSO treatment). This increase in the p53 protein staining in the presence of estrogen,
correlated with the estrogen-mediated increase in the p53 protein level we described earlier in the
Western blot analysis. When the cells were treated with etoposide, the p53 nuclear staining
increased (Figure 15A, etoposide treatment). Interestingly, some p53 remained localized to the
cytoplasm. Importantly, prolonged estrogen treatment did not block the etoposide-mediated p53
protein nuclear localization, but in fact moderately increased it (Figure 15A, etoposide
treatment). When the cells were treated with Nutlin-3, the p53 protein staining increased
dramatically in the nuclei while estrogen did not appear to have any significant effect (Figure
15A, Nutlin-3 treatment). The size of the nuclei, however, appeared to be smaller when estrogen
was added to the Nutlin-3 treatment (Figure 15A, Nutlin-3 treatment, DAPI staining).
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In addition to examining the effect of prolonged estrogen treatment on the p53 protein
cellular localization in the MCF-7 cells, we also examined how estrogen treatment affected the
cellular localization of the Mdm2 protein in these cells. Importantly, earlier we observed by
Western blot analysis that prolonged estrogen treatment increased both the basal and the druginduced Mdm2 protein levels. Concomitantly with the Western blot data, it seemed that estrogen
treatment moderately increased the nuclear localization of the basal and the etoposide-induced
Mdm2 protein (Figure 15A, DMSO and etoposide treatments). Interestingly, both the Mdm2 and
the p53 proteins were evident in punctate nuclear foci before and after estrogen treatment. When
the cells were treated with Nutlin-3, the Mdm2 protein staining increased dramatically in the
nuclei of the cells, whereas estrogen addition to the treatment did not appear to have any
significant effect (Figure 15A, Nutlin-3 treatment).
In the ZR75-1 cells, in parallel to what we observed by the Western blot analysis of the
p53 and Mdm2 protein levels, estrogen did not appear to have any effect on neither the p53 nor
the Mdm2 cellular localization in the absence and in the presence of the drug treatments (Figure
15B).
In conclusion, we observed that in MCF-7 breast cancer cells prolonged estrogen
treatment did not block the basal and the drug-induced p53 protein nuclear localization. This
suggests that the estrogen-mediated inhibition of the p53 target gene puma expression was not
due to a decrease in the nuclear localization of the p53 protein in the presence of estrogen.
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Figure 15: Prolonged estrogen treatment increased the nuclear localization of p53 and Mdm2
in untreated and etoposide treated MCF-7 cells, while the cellular localization of p53 and
Mdm2 did not change after estrogen treatment in the ZR75-1 cells. MCF-7 (A) and ZR75-1 (B)
cells were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48 hours
and 10 μM Nutlin-3 (NUT) for 24 hours. Immunofluorescence was carried out for p53 and
Mdm2 proteins. Nuclear DNA was stained with DAPI. Confocal images were collected by
PerkinElmer UltraVIEW ERS Spinning Disc Microscope. Representative images of cells from
three independent experiments are shown.
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In the MCF-7 breast cancer cells, estrogen treatment alone or in combination with
etoposide and Nutlin-3 treatments, increased the protein levels of Mdm2 without decreasing the
protein levels of p53. In parallel, we observed that both the basal and the drug-induced
expression of the p53 target gene puma was inhibited in the presence of estrogen. In the
following experiment we hypothesized that though estrogen treatment did not reduce the p53
protein levels, the estrogen-mediated inhibition of the p53 target gene puma mRNA expression
was due to reduced p53 protein recruitment to the p53-resposive elements (p53-REs) in the puma
gene.
To determine if prolonged estrogen treatment decreased the ability of the nuclear p53
protein to interact with the p53-REs in the puma gene, we carried out quantitative chromatin
immunoprecipitation (ChIP) experiments. Additionally, by this method we also examined the
p53 protein recruitment to the p53-REs in the mdm2 and p21 genes. As expected, we observed
that both etoposide and Nutlin-3 treatments increased the p53 protein recruitment to the p53-REs
in all three genes that we examined (Figure 16A, compare black bars only). Evidently, the p53
protein recruitment was higher in the Nutlin-3 treatment than in the etoposide treatment, which
correlated with higher p53 protein level in the Nutlin-3 treatment when analyzed by a Western
blot. In contrast to our hypothesis, however, estrogen treatment did not significantly affect the
p53 protein recruitment to the puma gene (Figure16A, compare black and gray bars, p>0.05).
And similarly, estrogen treatment did not affect the p53 protein recruitment to the mdm2 and p21
genes (Figure 16A, compare black and gray bars, p>0.05).
The Mdm2 protein is known to be recruited to the chromatin in a p53-dependent manner
(White et al. 2006). And in fact, in addition to regulating the p53 protein stability, Mdm2 directly
inhibits the p53 protein transcriptional activity by co-localizing with p53 on the chromatin
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(Momand et al. 1992, Oliner et al. 1993, Thut et al. 1997, Wu et al. 1993). Importantly, a
chromatin-associated and transcriptionally incompetent p53-Mdm2 complex has been detected in
various cancer cell lines that over-express Mdm2, where the Mdm2 protein localizes to the p53REs in the p53 target genes (Arva et al. 2005). Because of our observation of increased Mdm2
following estrogen treatment and the existing evidence in the literature, we hypothesized that the
estrogen-mediated decrease in the puma mRNA expression was due to increased Mdm2 protein
recruitment to the p53-REs in the puma gene.
Similar to the p53 protein, to determine if prolonged estrogen treatment affected the
ability of the Mdm2 protein to interact with the p53-REs in the puma gene, we carried out
quantitative ChIP experiments. As a control, we also examined the effect of estrogen treatment
on the Mdm2 protein recruitment to the p53-REs in the mdm2 and p21 genes. First we examined
how the drug treatment alone (etoposide and Nutlin-3) affected the Mdm2 protein recruitment to
the chromatin. We observed that etoposide treatment did not affect the relative binding of the
Mdm2 protein to the puma p53-REs, while Nutlin-3 treatment increased Mdm2 recruitment to
the puma p53-REs by 1.5 folds (Figure 16B, compare black bars in puma). Similarly, Mdm2
protein recruitment to the p53-REs of the mdm2 and p21 genes also increased only in the Nutlin3 treated cells (Figure 16B, compare black bars in mdm2 and p21). When we examined how
estrogen affected the Mdm2 protein recruitment to the chromatin, we observed that in the
presence of estrogen, there was a trend of a slightly higher levels of Mdm2 protein recruitment in
etoposide and Nutlin-3 treatments (Figure 16B, compare black and gray bars), but the increase
was not significant (p>0.05).
In conclusion, our observations suggest that the estrogen-mediated inhibition of the basal
and the drug-induced puma mRNA expression in the MCF-7 breast cancer cells was not due to a
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decrease in the p53 protein interaction with the p53-REs in the puma gene. Furthermore, we
determined that in the presence of a prolonged estrogen treatment, though the cellular Mdm2
protein level increased, estrogen did not significantly increase the Mdm2 protein recruitment to
the p53-REs in the puma gene.
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Figure 16: Prolonged estrogen treatment did not significantly affect the recruitment of the p53
and Mdm2 proteins to the p53-REs of puma, mdm2 and p21 genes in the MCF-7 cells. MCF-7
cells were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48 hours
and 10 μM Nutlin-3 (NUT) for 24 hours. 400 μg of cross-linked and sonicated whole cell lysates
were subjected to chromatin immunoprecipitation using antibodies against p53 (A) and Mdm2
(B). ChIP with non-specific IgG was done to subtract the background. Immunoprecipitated DNA
was amplified by real-time quantitative PCR with primers and FAM-labeled probes for p53-REs
in puma, mdm2 and p21 genes (See table 2 on page 22). Values were normalized to IgG and
inputs, followed by normalization to the DSMO samples. Graphs show means and standard
errors of three independent experiments. The p-values comparing p53 and Mdm2 recruitments to
the chromatin in the absence and in the presence of estrogen were greater than 0.05 (calculated
by student t-test), suggesting that the changes in the relative binding of p53 and Mdm2 to the
p53-resposive elements under the different treatments were not significant.
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So far in this study, we observed that in the MCF-7 breast cancer cells both the basal and
the etoposide-induced expressions of the p53 target gene puma were strongly inhibited by
prolonged estrogen treatment. In contrast, in the ZR75-1 cells the basal and the etoposideinduced puma mRNA expressions were not affected by prolonged estrogen treatment. Because
estrogen treatment did not reduce the p53 protein level in the MCF-7 cells, we concluded that the
decrease in the puma expression was not due to increased p53 degradation. Furthermore, by
carrying out ChIP experiments we demonstrated that prolonged estrogen treatment did not
reduce the p53 protein recruitment to the chromatin of puma. Importantly, since estrogen
treatment robustly up-regulated the levels of the Mdm2 protein in the MCF-7 but not in the
ZR75-1 cells, we hypothesized that the increased Mdm2 protein recruitment to the p53-REs in
the puma gene was the reason for the estrogen-mediated inhibition of puma expression.
However, though prolonged estrogen treatment increased the total cellular Mdm2 protein level in
the MCF-7 cells, ChIP experiments revealed that prolonged estrogen treatment did not increase
the recruitment of the Mdm2 protein to the chromatin in these cells.
Nonetheless, a possibility exists that the ChIP experiments performed after prolonged
estrogen treatment (five days) do not represent the p53 and Mdm2 dynamic mode of interaction
with the chromatin (White et al. 2006). Therefore, in the following experiments we asked similar
questions with regards to how estrogen affects the p53-Mdm2 pathway as we did in the earlier
experiments (by assessment of p53 target genes expression, p53 and Mdm2 protein levels, and
p53 and Mdm2 recruitment to the chromatin), but the estrogen treatment duration was much
shorter.
Initially, we carried out quantitative real-time RT-PCR experiments to determine if the
short-term estrogen treatment (24 hours) of MCF-7 cells inhibited the basal expression of puma
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and p21 mRNA as the prolonged estrogen treatment did. Additionally, to determine if the effect
of estrogen on the p53 target genes transcription was dose-dependent, the 24 hour estrogen
treatments were done at increasing concentration (5, 10 and 100 nM). We hypothesized that
since the five day estrogen treatment robustly inhibited the basal expression of puma and p21
mRNA, then the shorter duration of estrogen treatment would have a similar effect. And indeed,
we observed that in the MCF-7 cells estrogen treatment for 24 hours significantly reduced the
basal expressions of the p53 target genes puma and p21 (Figure 17A, compare black bars), while
the basal expression of mdm2 was not affected by estrogen (Figure 17A, compare black bars).
In addition, we also examined how the short-term estrogen treatment (24 hours) affected
the etoposide-mediated up-regulation of the p53 target genes expression. Evidently, earlier in this
study we showed that after a prolonged estrogen treatment (5 days), the etoposide-mediated
expression of puma mRNA was inhibited in the MCF-7 cells. We observed that etoposide
treatment alone increased the transcription from the puma, mdm2 and p21 genes in the MCF-7
cells (Figure 17A, compare black and gray bars in no estrogen samples). In parallel to the longterm estrogen treatment, we observed that etoposide-mediated expression of puma was inhibited
in the presence of a short-term estrogen treatment (Figure 17A, compare gray bars).
Interestingly, the effect of estrogen was not dose-dependent, as the differences between the
increasing concentrations of estrogen were not significant (Figure 17A, compare gray bars,
p>0.05). Additionally, in contrast to the long-term estrogen treatment, the short term estrogen
treatment also inhibited the etoposide-mediated mdm2 mRNA expression (Figure 17A, compare
gray bars). Although the increasing concentrations of estrogen appeared to inhibit the etoposidemediated expression of the mdm2 mRNA in a dose-dependent manner, the changes were not
significant (Figure 17A, compare gray bars, p>0.05).

53

Because in the ZR75-1 cells prolonged estrogen treatment did not inhibit the basal and
the etoposide-mediated expressions of the p53 target genes (puma, mdm2 and p21), we
hypothesized that a short-term estrogen treatment would have a similar effect on the p53 target
genes expression in these cells. And indeed, we observed that the short-term estrogen treatment
had no effect on the basal and the etoposide-induced expressions of the puma, mdm2 and p21
genes (Figure 17B).
In conclusion, we observed that estrogen treatment for 24 hours, similar to the prolonged
estrogen treatment, affected both the basal and the DNA damage-induced expressions of the p53
target genes in the MCF-7, but not in the ZR75-1 cells. Importantly, we observed that the basal
expressions of puma and p21 genes were inhibited by both prolonged and short-term estrogen
treatments, and the etoposide-induced puma expression was also inhibited by both estrogen
treatment conditions. But interestingly, the effect of short-term estrogen treatment differed from
the prolonged estrogen treatment with regards to the etoposide-mediated induction of the mdm2
mRNA expression. Specifically, while the etoposide-induced mdm2 mRNA expression was not
affected by the prolonged estrogen treatment, it was inhibited by the short-term estrogen
treatment.
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Figure 17: In MCF-7 cells, short-term estrogen treatment inhibited basal expression of puma
and p21 genes and also inhibited etoposide-mediated expression of puma and mdm2 genes,
while in ZR75-1 cells estrogen did not significantly affect puma, mdm2 and p21 genes
expression. MCF-7 and ZR75-1 cells were treated with 5, 10 and 100 nM estrogen (E2) for 24
hours and with 50 µM etoposide (ETOP) for 3 hours. Relative mRNA levels of puma, mdm2 and
p21 transcripts in MCF-7 (A) and ZR75-1 (B) cells were determined by quantitative real-time
RT-PCR. Values were normalized to DMSO samples and actin levels. Graphs show means and
standard errors of three (MCF-7) and two (ZR75-1) independent experiments. * p < 0.05
(determined by student t-test).
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In the above RT-PCR experiment, we observed that the short-term estrogen treatment
inhibited the basal expression of puma mRNA and also inhibited the etoposide-mediated
inductions of puma and mdm2 mRNA transcripts in the MCF-7 cells but not in the ZR75-1 cells.
Therefore, we wanted to determine the corresponding protein levels of Mdm2 and p53 in the two
cell lines. Additionally, to determine if the effect of estrogen on the Mdm2 and p53 proteins was
dose-dependent, the 24 hour estrogen treatment was done at increasing concentration of 5, 10
and 100 nM. We hypothesized that similar to the prolonged estrogen treatment, the short-term
estrogen treatment would also increase the protein level of Mdm2. Interestingly, we observed
that in MCF-7 cells only the 10 nM estrogen treatment increased the protein level of Mdm2,
while the 5 and the 100 nM estrogen treatments had no effect on the Mdm2 protein level (Figure
18A, compare lanes 1-4). Surprisingly, in the ZR75-1 cells, in contrast to the prolonged estrogen
treatment where estrogen did not affect the Mdm2 protein level, the 5 and the 10 nM short-term
estrogen treatments increased Mdm2 (Figure 18B, compare lanes 1-4).
In addition to examining the effect of the short-term estrogen treatment on the basal
protein level of Mdm2, we also studied how estrogen affects the Mdm2 protein level in the
presence of etoposide. The etoposide treatment was done for three hours in the absence or in the
presence of a 24 hour estrogen treatment. In contrast to the 48 hour etoposide treatment (that was
done in conjunction with the prolonged estrogen treatment protocol) where etoposide upregulated the Mdm2 protein level, the three hour etoposide treatment did not affect the Mdm2
protein level in the MCF-7 cells (Figure 18A, compare lanes 1-5). Similarly, the three hour
etoposide treatment did not affect the protein level of Mdm2 in the ZR75-1 cells (Figure 18B,
compare lanes 1-5). In MCF-7 cells, when etoposide treatment was combined with 5 or 10 nM
estrogen the Mdm2 protein levels increased, while the 100 nM estrogen treatment had no effect
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(Figure 18A, compare lanes 5-8). In the ZR75-1 cells, when etoposide treatment was combined
with 10 nM estrogen the Mdm2 protein level decreased, while the 5 and 100 nM estrogen had no
effect (Figure 18B, compare lanes 5-8). In conclusion, it appeared that the short-term estrogen
treatment affected the Mdm2 protein levels in both MCF-7 and ZR75-1 cells, but the effect was
not dose-dependent. Furthermore, the effect of the short-term estrogen treatment on the Mdm2
protein level appeared to be sporadic as independent repeat experiments for the Mdm2 protein
Western blot showed different changes in the Mdm2 protein level in response to the estrogen
treatment (data not shown).
We also examined if the short-term estrogen treatment had any effect on the basal and the
etoposide-induced p53 protein expression. We observed that in both MCF-7 and ZR75-1 cells,
etoposide treatment for three hours increased the p53 protein level (Figures 18A and 18B,
compare lanes 1-5). In the MCF-7 cells, the basal p53 protein level increased after 5 and 10 nM
of short-term estrogen treatment, but not after 100 nM of estrogen (Figure 18A, compare lanes 14). The increase in the p53 protein level correlated with the earlier experiments, where prolonged
estrogen treatments were carried out. In the ZR75-1 cells, short-term estrogen treatment had no
effect on the p53 protein level (Figure 18B, compare lanes 1-4), and this again correlated with
the effect of the prolonged estrogen treatment that we examined earlier. Interestingly, while
estrogen treatment did not affect the drug-induced p53 protein level in the ZR75-1 cells (Figure
18B, compare lanes 5-8), estrogen further up-regulated the etoposide-induced p53 protein level
in the MCF-7 cells (Figure 18A, compare lanes 5-8).
In addition, we also examined if the short-term estrogen treatment affected the ERα
protein levels. We observed that similarly to the five day estrogen treatment, estrogen treatment
for 24 hours decreased the ERα protein levels in both MCF-7 and ZR75-1 cells in the absence
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and in the presence of etoposide (Figures 18A and 18B, compare lanes 1-4, 5-8). This result,
similar to the prolonged estrogen treatment, supported what other investigators have reported in
the literature with regards to how estrogen affects the ERα protein stability (Callige and RichardFoy 2006).
In conclusion, in both MCF-7 and ZR75-1 cells short-term estrogen treatment did not upregulate the Mdm2 protein level in a concentration-dependent manner and in fact there was no
consistency between the replicate experiments (data not shown). Below only one of four
different experiments for Mdm2 Western blots is shown (Figure 18). Since the estrogen
treatment was relatively short, this observation may suggest that the Mdm2 protein level changes
wildly and/or oscillates in both MCF-7 and ZR75-1 cells, but after a five day estrogen treatment
the Mdm2 protein level becomes stably elevated in the MCF-7 cells but not in the ZR75-1 cells.
The short-term estrogen treatment, however, did not reveal conclusively what effect estrogen had
on the Mdm2 protein expression. Importantly, the effect of the 24 hour estrogen treatment on the
p53 protein level was consistent between the independent replicate experiments, where each time
estrogen treatment up-regulated both the basal and the etoposide-induced p53 protein levels in
the MCF-7 cells but not in the ZR75-1 cells. This observation, however, was quite surprising as
estrogen treatment decreased the expression of some of the p53 target genes in the MCF-7 cells.
Therefore, to determine if estrogen affected the p53 protein recruitment to the chromatin and
whether that was the reason for the reduced p53 target genes expression, we carried out the
following ChIP experiments.
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Figure 18: Assessment of Mdm2, p53 and ERα protein levels after a short-term estrogen
treatment in the absence and in the presence of etoposide. MCF-7 and ZR75-1 cells were
treated with 5, 10 and 100 nM estrogen (E2) for 24 hours and with 50 µM etoposide (ETOP) for
3 hours. Mdm2, p53, ERα and Actin protein levels of whole cell lysates from MCF-7 (A) and
ZR75-1 (B) cells were analyzed by Western blot.
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To determine if the short-term estrogen treatment affected the ability of the p53 protein to
interact with the p53-REs in puma and mdm2 genes in the MCF-7 cells, we carried out
quantitative ChIP experiments. Earlier, we observed that in MCF-7 cells estrogen treatment
decreased the basal mRNA level of puma and the etoposide-induced mRNA levels of puma and
mdm2. We hypothesized that this occurred due to reduced p53 recruitment to the chromatin.
However, p53 ChIP experiments revealed that estrogen did not reduce the p53 protein
recruitment to the p53-REs in the puma and mdm2 genes (Figure 19A).
Though the short-term estrogen treatment did not robustly increase the Mdm2 protein
level as the prolonged estrogen treatment did, we hypothesized that the inhibition in the puma
and the mdm2 mRNA expression in the presence of estrogen could be due to increased Mdm2
protein recruitment to the chromatin. We observed, however, that neither etoposide nor estrogen
treatments affected the levels of the Mdm2 protein recruitment to the p53-REs in puma and
mdm2 genes (Figure 19B). Interestingly, the basal level of the Mdm2 protein on the p53-REs in
the puma gene was almost twice as high as the one on the p53-REs of the mdm2 gene, but again
it did not change in the presence of the treatments (Figure 19B).
Since the etoposide-induced mRNA expression from the puma and the mdm2 genes was
inhibited in the presence of estrogen, we examined if estrogen affected the RNA polymerase II
(RNAP II) recruitment to the chromatin. We hypothesized that since estrogen inhibited the
expression of these genes, it was possible for estrogen to affect the RNAP II recruitment to these
genes. We observed, however, that estrogen did not significantly affect the RNAP II recruitment
to the transcription start sites (TATA boxes) of the puma and the mdm2 genes (Figure 19C). The
transcription start sites in the two genes are located in close proximity to the p53-REs (Gomes
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and Espinosa 2010, Xiao et al. 1998), and therefore the same primers that were used for the p53
and Mdm2 ChIP experiments were also used for the RNAP II ChIP experiments.
In conclusion, the results from the p53 and Mdm2 ChIP experiments after the short-term
estrogen treatment correlated with the results from the ChIP experiments after a prolonged
estrogen treatment. Estrogen treatment inhibited the expression of certain p53 target genes, but
did not affect the recruitment of the p53 or the Mdm2 proteins to the chromatin of these genes.
Interestingly, estrogen also had no effect on the RNAP II recruitment to the chromatin of the
inhibited genes. It is possible, however, that estrogen decreased the recruitment of the
phosphorylated form of RNAP II that is involved in the elongation of RNAP II along the gene
during the transcription process (RNAP II phosphorylated at Ser2 in the C-terminal domain
(Komarnitsky et al. 2000)).
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Figure 19: Short-term estrogen treatment
had no significant effect on the p53,
Mdm2 and RNAP II proteins recruitment
to the puma and mdm2 genes in the
MCF-7 cells. MCF-7 cells were treated
with 10 nM estrogen (E2) for 24 hours and
50 μM etoposide (ETOP) for three hours.
400 μg of cross-linked and sonicated whole
cell lysates were subjected to chromatin
immunoprecipitation using antibodies
against p53 (A), Mdm2 (B) or RNAP II (C).
ChIP with non-specific IgG was done to
subtract
the
background.
Immunoprecipitated DNA was amplified by
real-time quantitative PCR with primers
and FAM-labeled probes for p53-REs in
puma and mdm2 genes. Values were
normalized to IgG and inputs.
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3.1.3 Discussion
In this study we began to examine the role of the Mdm2 oncoprotein in the estrogenmediated proliferation of ERα+ breast cancer cells. Since estrogen is known to promote Mdm2
over-expression in breast cancer cells, we hypothesized that the estrogen-mediated cell
proliferation is dependent on Mdm2. Importantly, we observed that there was a direct correlation
between the estrogen-mediated proliferation of the MCF-7 breast cancer cells and the increased
Mdm2 protein expression in the presence of estrogen in these cells. Exogenous Mdm2 overexpression in the MCF-7 cells has been shown to promote growth advantage (Saji et al. 1999),
but the mechanism for this is not known. Furthermore, since Mdm2 is important in regulating the
p53 tumor suppressor, and in fact is considered to be a major negative regulator of p53, we
proposed that the increased cell proliferation in the presence of estrogen occurred through
inhibition of the p53 pathway by Mdm2.

Analysis of estrogen effects on the expression and function of the p53 protein
Since one of the major functions of Mdm2 is to negatively regulate p53 by promoting its
degradation, we hypothesized that in the presence of estrogen the induced Mdm2 overexpression would lead to p53 degradation. However, it was surprising to see that in the MCF-7
breast cancer cells, while estrogen increased the Mdm2 protein level, the p53 protein level did
not decrease, but in fact increased as well. Interestingly, two independent studies have reported
that estrogen can stabilize the p53 protein level in the MCF-7 cells (Okumura et al. 2002a) and
that the estrogen receptor α (ERα) protects p53 from deactivation by Mdm2 by forming a
complex with the p53 protein (Liu G. et al. 2000). Taken together, the evidence in the literature
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and our data suggest that the p53 protein stability can be sustained in the presence of estrogen
even when the Mdm2 protein level increases.
We hypothesized that since estrogen increased the expression of the Mdm2 protein, but
the p53 protein stability was sustained, then perhaps the p53 transcriptional activity on the
chromatin was affected. Importantly, in addition to regulating the p53 protein stability, Mdm2 is
known to directly inhibit the p53 protein transcriptional activity on the chromatin by colocalizing with p53 at the p53-RE sites (Momand et al. 1992, Oliner et al. 1993, Thut et al. 1997,
Wu et al. 1993). By co-localizing with p53 on the chromatin, Mdm2 is believed to hinder the
interaction of the p53 protein with the transcriptional co-activators, which in turn can block
transcription initiation (Lin et al. 1994, Thut et al. 1997). To determine if the p53 transcriptional
activity is affected by estrogen, we looked at the effect of estrogen on the p53 target genes
expression that are involved in three different pathways: puma (apoptosis), mdm2 (p53 negative
regulation), and p21 (growth arrest). We observed that in the MCF-7 cells prolonged estrogen
treatment robustly inhibited both the basal and the drug-induced (etoposide and Nutlin-3)
expression of the pro-apoptotic p53 target gene puma. Additionally, we also observed that
estrogen robustly inhibited the basal expression of the growth-arrest p53 target gene p21, but had
no effect on its expression in the presence of the stress-inducing stimuli. This inhibition,
however, occurred while estrogen in fact increased the basal p53 protein level and did not
significantly change the drug-induced p53 protein level.
Since estrogen reduced the expression of the puma gene, but did not affect the p53
protein level, we conducted quantitative chromatin immunoprecipitation (ChIP) assays to see if
the decrease in the puma transcription was due to reduced p53 protein recruitment to the
chromatin. We saw, however, that the p53 protein recruitment to the puma p53-REs did not
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change in the presence of estrogen. This suggests that estrogen may have affected the p53 protein
activity at specific p53 target genes without substantially blocking the p53 protein DNA binding
ability.
Since estrogen increased the basal- and the drug-induced Mdm2 protein level, we also
examined if the estrogen-mediated inhibition of puma transcription was due to increased Mdm2
protein recruitment to the p53-REs in the puma gene. We observed, however, that estrogen did
not lead to a significant increase in the Mdm2 protein recruited to the chromatin. These results
suggest that the increased Mdm2 protein expression in the presence of estrogen is not sufficient
to promote p53 degradation or to increase Mdm2 protein recruitment to the chromatin, but a
possibility exists that the p53 transcriptional output is controlled by Mdm2 at an epigenetic level
and that the changes in the Mdm2 protein level in the presence of estrogen are sufficient to affect
the p53 protein activity on the chromatin. Evidently, Mdm2 has been shown to repress the p53mediated transcription by promoting ubiquitination of histone H2 (Minsky and Oren 2004) and
by recruiting methyltransferases to methylate p53 and histone H3 at target promoters (Chen L. et
al. 2010). Importantly, the binding of the p53 protein to the puma promoter facilitates acetylation
of the core histones (H3 and H4), which, in turn, leads to opening of the chromatin structure and
transcriptional activation (Kaeser and Iggo 2004, Wang P. et al. 2007). Additionally, the
estrogen-mediated increase in the Mdm2 protein may lead to the p300 transcriptional coactivator ubiquitination and subsequent degradation that could, in turn, result in reduced
acetylation of p53 (Jin et al. 2004, Jin et al. 2002) and subsequently reduce p53 transcriptional
activity. The role of the p300 acetyltransferase may be important in the estrogen-mediated
inhibition of puma, since the expression of the puma gene is regulated by p300 (Iyer et al. 2004).
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In addition, although estrogen treatment decreased the etoposide-induced p53 target gene
puma transcription without reducing the p53 protein level, it is possible that estrogen affected the
post-translational modifications on the p53 protein. For example, estrogen was shown to inhibit
the resveratrol-activated p53 in the MCF-7 cells in part by interfering with the post-translational
modifications of p53, which have been shown to be essential for p53-dependent DNA binding
and consequent stimulation of downstream pathways (Zhang S. et al. 2004a). We observed that
in the MCF-7 cells, p53 phosphorylation at Ser15 after etoposide treatment was very marginal
and was not affected by estrogen (data not shown). For further investigation, it will be important
to check if estrogen affects the post-translational modifications of the other key p53 residues that
have been shown to be required for the activation of puma transcription (e.g. acetylation at
Lys120, Lys164, Lys373, Lys382, and phosphorylation at Ser46) (Vousden and Prives 2009).
Perhaps changes in the recruitment of the modified form of the p53 protein to the chromatin
could explain the reduced puma transcription in the presence of estrogen.
It is highly likely that estrogen acts in a number of coordinated ways to block puma
transcription. For example, estrogen can induce transient cyclical DNA methylation of active
promoters that leads to transcription inhibition (Kangaspeska et al. 2008, Metivier et al. 2008). In
turn, the puma gene is prone to be highly methylated, which results in reduced puma expression
(Garrison et al. 2008). Therefore, it is possible that estrogen may promote puma gene
methylation and thus inhibit its expression. Furthermore, estrogen has also been shown to upregulate Myc expression (Rodrik et al. 2006). Importantly, adjacent to the location of the p53
binding site, the puma gene promoter contains E boxes which serve as an inhibitory binding site
for Myc (Garrison et al. 2008). Therefore, it is possible that by inducing Myc expression
estrogen can inhibit the expression of puma. In addition, the ERα protein can also bind to the p53
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protein directly and thus potentially repress the p53 transcriptional activity on the chromatin as
well (Konduri et al. 2010, Liu W. et al. 2006, Sayeed et al. 2007).
Because we did not obtain a direct evidence that estrogen affected the p53 protein activity
when the puma expression was inhibited, a possibility exists that estrogen inhibited puma
expression in a p53-independent manner. Therefore, it is important to determine if other
transcription factor of the p53 family genes (p73 and p63) are affected by estrogen. For example,
in response to a variety of stimuli p73 has been shown to activate puma gene expression by
binding to the same p53-REs in the puma promoter as the ones that the p53 protein binds to
(Matallanas et al. 2007, Melino et al. 2004, Ming et al. 2008). Therefore, it is possible that
estrogen inhibited the p73-mediated transactivation of puma, and not that of the p53 protein. In
support of this hypothesis, our preliminary experiments indicate that when p53 was knocked
down by shRNA, puma transcription was still induced by etoposide treatment (data not shown).

Analysis of estrogen effects on the Mdm2 expression
Interestingly, when we examined the mechanism of how estrogen regulates the
expression of Mdm2 we notice that while estrogen treatment increased the Mdm2 protein level,
analysis of the mdm2 mRNA level revealed that its expression was not significantly affected by
the estrogen treatment. This observation may suggest that the estrogen-mediated Mdm2 overexpression in the MCF-7 cells was due to increased mdm2 mRNA translation and/or due to
inhibition of the Mdm2 protein degradation. Importantly, this observation does not rule out the
possibility that estrogen regulates Mdm2 expression at the transcriptional level as well. In fact,
an earlier study clearly showed by Northern blot analysis that estrogen treatment does increase
the expression of the mdm2 mRNA transcripts in the MCF-7 cells (Gudas et al. 1995). And
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additionally, Arnold Levine’s group also showed that in the presence of estrogen there is an
increased RNAP II (RNA Polymerase II) recruitment to the mdm2 gene promoter in the MCF-7
cells (Hu et al. 2007).
To analyze the mdm2 mRNA expression in the absence and in the presence of estrogen
treatment, in the quantitative real-time RT-PCR experiment we used primers that target an
internal region of the mdm2 mRNA transcript (exons 6 through 7). This region is known to be
often spliced out during the mdm2 mRNA processing (Bartel et al. 2002, Bartel et al. 2004).
Therefore, a possibility exists that not all the mdm2 transcripts (full length and spliced variants)
were detected by this method. Hence, it will be important to systematically evaluate the
expression of all the mdm2 mRNA isoforms in the absence and in the presence of estrogen. This
should be done by Northern blot analysis (using random labeling in order to detect all the
possible isoforms of mdm2) as well as by quantitative real-time RT-PCR (using primers designed
to target a specific region in the mdm2 mRNA transcript that is common for all mdm2 isoforms,
and also primers that can detect and distinguish mdm2 mRNA expression specifically from the
P1 and the P2 promoters of the mdm2 gene). These methods will allow us to see the estrogenmediated changes in the different isoforms of the mdm2 mRNA transcripts and to correlate them
with the changes in the Mdm2 protein expression.
Interestingly, we observed that both the untreated and the estrogen-treated MCF-7 cells
appeared to have multiple forms of the Mdm2 protein, as the Mdm2 Western blot showed several
bands for Mdm2. The mdm2 gene consists of 12 exons. The mRNA transcripts of the mdm2 gene
often lack several exons, as they are spliced out during mRNA processing (Bartel et al. 2002). In
fact, alternative splicing of the mdm2 gene has been shown to result in over 40 different mdm2
splice variants that have been identified in both normal and tumorous tissues (Bartel et al. 2004,
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Harris 2005). Importantly, the occurrence of high instances of the mdm2 mRNA splicing has
been associated with malignant cancer phenotypes (Bartel et al. 2001). In addition, the function
of the Mdm2 protein is known to be modulated by post-translational modifications, such as
ubiquitination, phosphorylation and sumoylation (Meek and Knippschild 2003). Therefore, the
increase in the level of the different forms of the Mdm2 protein in the presence of estrogen
suggest that estrogen may play an important role in the regulation of the mdm2 transcript splicing
and/or the post-translational modifications of the Mdm2 protein. Interestingly, a clinical study
examining the correlation between the over-expression frequency of the mdm2 splice variants
and the clinicopathological features of breast cancers showed that there was no significant
correlation between the two. However, cases with spliced mdm2 transcripts tended to be of a
more aggressive type of breast tumors (Hori et al. 2000).
Furthermore, to determine if estrogen regulates Mdm2 expression at the transcriptional or
the translational levels, it will be important to examine the changes in the Mdm2 expression after
estrogen treatment in the presence of a transcription inhibitor (α-amanitin) and a protein
biosynthesis inhibitor (cyclohexamide). If estrogen regulates mdm2 transcription, then in the
presence of α-amanitin estrogen will not be able to up-regulate mdm2 expression. And in turn, if
estrogen regulates Mdm2 translation, then in the presence of cyclohexamide estrogen will not be
able to up-regulate Mdm2 protein expression. It is important to keep in mind, however, that both
mechanisms can occur simultaneously. In addition, it is also possible that estrogen regulates
Mdm2 protein stability. Therefore, a pulse-chase cell labeling method (examining the level of
[35S]methionine-labeled Mdm2) will determine if the half-life of the Mdm2 protein increases in
the presence of estrogen. If estrogen affects the stability of the Mdm2 protein and thus increases
the half-life of Mdm2, than [35S]methionine-labeled cells that were grown in the presence of
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estrogen will retain more of the [35S]methionine-labeled Mdm2 over-time than the
[35S]methionine-labeled cells that were grown in the absence of estrogen.

Estrogen signals towards the anti-apoptotic pathway by oppositely regulating the expression of
Puma and Bcl-2
It has been shown earlier that the pro-apoptotic gene puma is among the genes that are
expressed at reduced levels after estrogen treatment (Tozlu et al. 2006). We observed that though
both MCF-7 and ZR75-1 cell lines are ERα+, only in the MCF-7 cells the basal and the
etoposide-induced puma mRNA expression was inhibited after estrogen treatment. This suggests
that the ERα status in the breast cancer cells is not sufficient for the estrogen-mediated inhibition
of puma gene expression. Evidently, in the MCF-7 cells, estrogen inhibited the basal and the
drug-induced puma mRNA expression and in parallel up-regulated the Mdm2 protein level under
the same conditions. Therefore, it is possible that estrogen requires Mdm2 to inhibit the puma
mRNA expression. To further investigate this observation, it will be important to test if estrogen
will still inhibit puma expression when the Mdm2 protein over-expression in blocked.
Estrogen has also been shown to inhibit apoptosis in the MCF-7 cells by inducing the
expression of the anti-apoptotic gene, bcl-2 (Perillo et al. 2000). Interestingly, we saw a
coordinated up-regulation of Bcl-2 and a down-regulation of Puma in the MCF-7 cells. This
suggests that estrogen may be signaling towards the anti-apoptotic pathway by decreasing Puma
and by simultaneously increasing Bcl-2, and thus estrogen increases cell survival during the
induced cell proliferation. Evidently, estrogen-derived oxidants have been shown to result in
oxidative stress and DNA adducts (Chen Y. et al. 2000, Mobley and Brueggemeier 2004, Yared
et al. 2002). Therefore, it is possible that the DNA-damaging effects of estrogen in combination
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with suppression of the intrinsic apoptotic pathway could set the stage for the cancer cells to
emerge from cell populations sustaining the DNA damage.

Summary of conclusions
1) Estrogen robustly up-regulated the expression of the Mdm2 protein in breast cancer cells that
carry the SNP309 (TG) in the mdm2 gene (MCF-7 cells), but not in the cells that don’t
carry the SNP (ZR75-1 cells).
2) Estrogen-mediated Mdm2 over-expression correlated with increased cell proliferation.
3) Estrogen robustly inhibited both the basal and the drug-induced (etoposide and Nutlin-3)
puma mRNA expression and in parallel decreased the Puma protein level.
4) Estrogen appeared to signal towards the anti-apoptotic pathway by decreasing Puma and by
simultaneously increasing Bcl-2, and thus increasing cell survival during induced
proliferation.
5) While estrogen decreased the p53 target gene puma expression, estrogen did not lead to p53
degradation, p53 nuclear exclusion or decreased p53 interaction with the chromatin.
6) Though estrogen increased the Mdm2 protein level and slightly increased the nuclear
localization of Mdm2, estrogen did not increase the Mdm2 protein co-localization with the
p53 protein on the chromatin.
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Figure 20: Mdm2 plays a central role in the estrogen-mediated cell proliferation. The observed
estrogen-mediated cell proliferation correlated with the Mdm2 protein over-expression in the
MCF-7 cells. Our initial hypothesis was that the increased cell proliferation in the presence of
estrogen occurred through inhibition of the p53 pathway by Mdm2. However, the data suggest
that during this process Mdm2 targets other pathways as well. Specifically, we saw that the
estrogen-mediated increase in Mdm2 did not lead to p53 protein degradation or increased
Mdm2 co-localization with p53 on the chromatin. The pro-apoptotic p53 target Puma was
robustly inhibited in the presence of estrogen, and since estrogen simultaleously up-regulated
Mdm2 this suggests that Mdm2 may play a role in this process. And similarly, a posibility exists
that Mdm2 may play a role in the estrogen-mediated up-regulation of the anti-apoptotic protein
Bcl-2. Overall, the data suggest that during the estrogen-mediated cell proliferation several
pathways may be targeted by estrogen via Mdm2.
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3.2 Determination of the roles of Mdm2 and p53 in the estrogen-mediated breast cancer
cell proliferation.
3.2.1 Introduction
To investigate what role the Mdm2 protein plays during estrogen’s signaling in the breast
cancer cells, in the following part of this study we examined how the down-regulation of the
Mdm2 expression affects the estrogen-mediated cell proliferation. Because we observed a strong
correlation between the increased Mdm2 protein expression and cell proliferation in the presence
of estrogen, we predicted that decreasing Mdm2 expression in the presence of estrogen would
block cell proliferation. In addition, since Mdm2 is a major negative regulator of p53, we also
investigated if the estrogen-mediated cell proliferation occurred due to the inhibition of the p53
pathway by Mdm2 (see Figure 21 below).
To determine the contribution of Mdm2 and p53 to the estrogen-induced cell
proliferation, we transiently knocked down Mdm2 by siRNA and also generated stable cell lines
containing shRNAs for inducible knockdown of Mdm2 and p53. The doxycycline-inducible
shRNAs constructs targeting mdm2 and p53 using the mir-30 design (see Figure 5 on page 17
above) were a generous gift from Scott Lowe and Agustin Chicas form the Cold Spring Harbor
Laboratory. The shRNA-containing constructs (see Table 1 on page 18 above) were introduced
into the MCF-7 cells by retroviral gene transfer method. MCF-7 cells carrying various levels of
the mdm2 or the p53 shRNAs were generated (pools), and subsequently, stable clones were
selected by seeding the cells at limited densities (clones). Once the stable clonal cell lines
carrying inducible shRNAs for mdm2 and p53 were generated, we began to examine the roles
that the Mdm2 and p53 play during estrogen-mediated breast cancer cell proliferation.
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Figure 21: Examining the roles that Mdm2 and p53 play during the estrogen-mediated breast
cancer cell proliferation. Because there was a strong correlation between the increased Mdm2
protein expression and cell proliferation in the presence of estrogen, we investigated the role
that Mdm2 and its major negative target, p53, play during this process. We predicted that
decreasing Mdm2 expression in the presence of estrogen would block the estrogen-mediated cell
proliferation. And in turn, blocking the p53 pathway, by knocking down p53, would further
augment the estrogen-mediated cell proliferation.
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3.2.2 Results
In the previous section of this study, we observed that in the MCF-7 breast cancer cells
transcription of certain p53 target genes was inhibited in the presence of estrogen. Since estrogen
treatment increased the Mdm2 protein level in these cells, we hypothesized that Mdm2, a major
p53 inhibitor, played an important role in the estrogen-mediated inhibition of the p53 target
genes expression. To test this hypothesis, in the following experiment we transiently knocked
down Mdm2 by siRNA and examined if the estrogen-mediated inhibition of the p53 target genes
expression was relieved. Furthermore, since estrogen treatment did not increase the Mdm2
protein level in the ZR75-1 breast cancer cells and concomitantly did not robustly inhibit the
expression of the p53 target genes in this cell line, we also compared the effect of the Mdm2
knockdown in the presence of estrogen between the two cell lines.
We observed that in both MCF-7 and ZR75-1 cell lines, mdm2 siRNA reduced the Mdm2
protein level both in the absence and in the presence of the estrogen treatment (Figure 22A and
22C, compare lanes 1 and 5, and lanes 2 and 6, Mdm2) and also in the presence of an etoposide
treatment (Figure 22A and 22C, compare lanes 3 and 7, and lanes 4 and 8, Mdm2). Similarly, the
mdm2 mRNA expression was reduced in both cell lines after the Mdm2 knockdown by siRNA in
the presence of estrogen and etoposide treatments (Figure 22B and 22D, mdm2). Interestingly,
knockdown of Mdm2 did not influence the p53 protein levels in the absence or in the presence of
etoposide (Figure 22A and 22C, compare lanes 1-2 and 5-6, and lanes 3-4 and 7-8, p53).
Furthermore, we observed that in both cell lines Mdm2 knockdown dramatically increased the
p21 protein level, both in the presence and in the absence of estrogen and etoposide treatments
(Figure 22A and 22C, compare lanes 1-2 and 5-6, and lanes 3-4 and 7-8, p21). In correlation,
Mdm2 knockdown in the presence of estrogen resulted in increased expression of the p21 mRNA
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transcript, as determined by the quantitative real-time RT-PCR (Figure 22B and 22D, p21). And
only the basal level of the puma mRNA transcripts increased after the Mdm2 knockdown, while
the etoposide-mediated puma mRNA induction was not significantly affected (Figure 22B and
22D, puma).
In conclusion, in this experiment we observed that in both MCF-7 and ZR75-1 cell lines
Mdm2 knockdown in the presence of estrogen similarly increased the basal and the etoposideinduced p21 transcription and also increased the basal transcription of puma. Importantly, this
experiment shows that in both cell lines the p53 target genes expression was similarly affected
by the Mdm2 knockdown in the presence of estrogen. In addition (and surprisingly), we did not
observe an increase in the p53 protein level when the Mdm2 expression was blocked. Following
Mdm2 knockdown, however, the p53 target genes expression was up-regulated. This result
suggests that while the p53 protein level did not increase following Mdm2 knockdown, the
transcriptional activity of the p53 protein increased.

76

Figure 22: Mdm2 knockdown by siRNA potentiated the p53 transcriptional activity in the
presence of estrogen in both MCF-7 and ZR75-1 cell lines. MCF-7 and ZR75-1 cells were
transfected with 100 nM of non-specific or mdm2 siRNA. 24 hours following transfection, cells
were treated with 10 nM estrogen (E2) for 24 hours and 50 µM etoposide (ETOP) for 3 hours.
Mdm2, p53, p21 and Actin protein levels from whole cell lysates of MCF-7 (A) and ZR75-1 (C)
cells were analyzed by Western blot. Relative mRNA levels of puma, p21 and mdm2 genes in
MCF-7 (B) and ZR75-1 (D) cells were determined by quantitative real-time RT-PCR. Results
were normalized to control samples and actin values. Graphs show means and standard errors
of two independent experiments. * p<0.05 (determined by student t-test).
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In the following experiment, we wanted to determine if the Mdm2 protein overexpression in the presence of estrogen contributed to the estrogen-mediated breast cancer cell
proliferation. To achieve that, we examined the effect of the Mdm2 knockdown on the MCF-7
and ZR75-1 breast cancer cells proliferation in the presence of estrogen. Earlier in this study, we
observed that during cell proliferation in the presence of estrogen, estrogen increased the Mdm2
protein level in the MCF-7 cells but not in the ZR75-1 cells. Therefore, in the following
experiment we hypothesized that the Mdm2 knockdown in the presence of estrogen will inhibit
the MCF-7 cells proliferation to a greater extent than the ZR75-1 cells proliferation.
In the MCF-7 cells, we observed that Mdm2 knockdown by siRNA in the presence of
estrogen increased the percent of cells in the G1 phase and subsequently decreased the percent of
cells in the S phase (Figure 23A). Cell proliferation was measured by the MTT colorimetric
assay. In the MCF-7 cells, 18% inhibition of estrogen-mediated cell proliferation was observed
after the Mdm2 knockdown (Figure 23B). Etoposide treatment inhibited the estrogen-mediated
cell proliferation to a similar degree as the Mdm2 knockdown, while combination of etoposide
treatment and Mdm2 knockdown did not lead to any further inhibition of cell proliferation
(Figure 23B). In turn, the ZR75-1 cells appeared to be less sensitive to the Mdm2 knockdown
than the MCF-7 cells, since Mdm2 depletion inhibited their proliferation only by 11% (Figure
23C). The ZR75-1 cells, however, were more sensitive to the etoposide treatment than the Mdm2
knockdown, and combination of the Mdm2 knockdown and etoposide treatment further inhibited
cell proliferation (Figure 23C).
Importantly, in agreement with our hypothesis we observed that Mdm2 knockdown
inhibited the estrogen-mediated MCF-7 cells proliferation more robustly than the estrogen-
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mediated ZR75-1 cells proliferation. This suggests that the estrogen-mediated Mdm2 overexpression plays an important role during the estrogen-mediated breast cancer cell proliferation.

Figure 23: Mdm2 knockdown by siRNA inhibited the estrogen-mediated MCF-7 cells
proliferation more robustly than the estrogen-mediated ZR75-1 cells proliferation. (A) MCF-7
cells were transfected with 100 nM of non-specific or mdm2 siRNA. 24 hours following
transfection, cells were treated with 10 nM estrogen (E2) for 48 hours. At the end of the
treatments fluorescence activated cell sorting (FACS) was carried out. (B and C) Percent of cell
proliferation inhibition was determined by the MTT assay. MCF-7 and ZR75-1 cells were
transfected with 100 nM of non-specific or mdm2 siRNA. 24 hours following transfection, cells
were treated with 10 nM estrogen (E2) for 48 hours and following additional 24 hours cell were
treated with 50 μM etoposide (ETOP). Graphs show means and standard errors of three
independent experiments.
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During the transient transfections with the siRNA, we observed that the cells were
sensitive to the medium conditions, which made it difficult to conduct long term estrogen
treatments and to study cell proliferation. Therefore, we generated stable cell lines containing
shRNAs for inducible RNA interference. The doxycycline-inducible construct, carrying the
shRNA, contains a GFP expressing marker (see Figure 5 on page 17 for the construct map
details). When the MCF-7 cells carrying the shRNA for mdm2 were treated with 2 µg/ml
doxycycline for six days, we observed GFP expression as a sign for shRNA expression (Figure
24). Evidently, some GFP expression was visible in the absence of the doxycycline treatments,
suggesting that the construct was slightly leaky. When clonal cell lines were selected for the use
in the future experiments, we made sure to take this into consideration and selected only those
clones that did not express any GFP in the absence of the doxycycline treatment.

Figure 24: Assessment of the doxycycline-inducible construct expression in the MCF-7 cells.
MCF-7 cells with mdm2 shRNA (151656 pool) or control vector were treated with 2 µg/ml
doxycycline for six days to induce shRNA expression. Images show GFP fluorescence.
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The following experiment illustrates that generating clonal cell lines containing the
shRNA construct, increases the efficiency of the protein knockdown and the observed
phenotype. The clonal MCF-7 cell line carrying the shRNA for mdm2 (mdm2 shRNA 151656,
clone C4) was generated by limited dilution method from the MCF-7 mdm2 shRNA-containing
pool line (mdm2 shRNA 151656, pool). Importantly, the Mdm2 protein knockdown appeared to
be greater in the clonal line (Figure 25A, compare lanes 3-4 for the pool, and 5-6 for the clone,
Mdm2). Furthermore, the increase in the p21 protein was greater in the MCF-7 clonal cell line as
well (Figure 25A, compare lanes 3-4 for the pool, and 5-6 for the clone, p21). Interestinly, the
p53 protein level was not affected by the Mdm2 protein knockdown (Figure 25A, compare lanes
3-4 for the pool, and 5-6 for the clone, p53). This observation is in agreement with what we
observed earlier after Mdm2 knockdown with an siRNA. Importantly, the inhibition in cell
proliferation after the Mdm2 knockdown was more effective in the clonal cell line than the one
observed in the pool (Figure 25B, the MCF-7 cells proliferation is represented by the percent of
the mitochondrial activity of the cells that could be considered to be proportional to the number
of cells).
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Figure 25: Characterization of the clonal MCF-7 cell line containing the shRNA for mdm2.
MCF-7 cells with control vector, mdm2 shRNA (151656 pool) or mdm2 shRNA (151656 clone
C4) were treated with 2 µg/ml doxycycline for six days to induce shRNA expression. (A) Western
blot analysis of Mdm2, p53, p21 and Actin protein levels in whole cell extracts. (B) Cell
proliferation was measured by the MTT assay.
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Once we generated a clonal MCF-7 cell line with a good inducible Mdm2 knockdown,
we began to examine the efficiency of the Mdm2 knockdown and its effect on the p53 and the
p21 protein levels in the absence and in the presence of estrogen. Induction of the mdm2 shRNA
by doxycycline treatment reduced the Mdm2 protein level and dramatically increased the p21
protein level in the MCF-7 cells (Figure 26A, compare lanes 3 and 4, Mdm2). The p53 protein
level, however, was not affected by the Mdm2 knockdown (Figure 26A, compare lanes 3 and 4,
p53). Interestingly, previously we observed that a transient Mdm2 knockdown by siRNA also
did not affect the p53 protein level while the p53 target p21 increased dramatically.
The expression of the Mdm2 protein was also effectively blocked by the shRNA
induction in the presence of estrogen (Figure 26B, compare lanes 1-3-4, Mdm2), while in the
vector control cell line, doxycycline treatment had no effect on the Mdm2 protein level in the
absence and in the presence of estrogen (Figure 26B, compare lanes 5-8, Mdm2). Interestingly,
Mdm2 knockdown in the presence of estrogen promoted a greater up-regulation in the p21
protein level than in the absence of estrogen (Figure 26B, compare lanes 2 and 4, p21). We
noticed that estrogen treatment alone increased the p21 protein level in the mdm2 shRNAcontaining cell line, but not in the vector control cell line (Figure 26B, compare lanes 1 and 3,
and lanes 5 and 7, p21). In fact, in the vector control cell line, estrogen treatment decreased the
protein level of p21 (Figure 26B, compare lanes 5 and 7, p21). Due to the inconsistency in the
estrogen’s effect on the p21 protein level in the mdm2 shRNA-containing cell line and in the
vector control cell line (when the mdm2 shRNA was not expression, Figure 26B, compare lanes
1 and 3 and lanes 5 and 7, p21), we examined an additional MCF-7 clone (mdm2 shRNA
151656, clone A4). Interestingly, in that clone we observed a similar increase in the p21 protein
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level after estrogen treatment and an additive increase in the p21 protein level after the Mdm2
knockdown in combination with the estrogen treatment (data not shown).
Upon Mdm2 knockdown by shRNA, we also examined the changes in the ERα protein
level. The Mdm2 E3 ubiquitin ligase has been shown to regulate the ERα protein level via the
proteasomal degradation (Duong et al. 2007). We therefore, hypothesized that down-regulation
of the Mdm2 protein by shRNA will increase the protein level of the ERα. Surprisingly,
however, we observed that Mdm2 knockdown decreased the ERα protein level (Figure 26B,
compare lanes 1 and 2). This result suggests that in addition to regulating ERα degradation,
Mdm2 promotes ERα stability. Perhaps, in certain situations the ERα protein monoubiquitination by Mdm2 or simply the Mdm2-ERα complex formation is required for the protein
stability, and when the Mdm2 expression is down-regulated, the ERα protein level cannot be
sustained. In addition, similar to our earlier observations, estrogen treatment decreased the ERα
protein level (Figure 26B, compare lanes 1 and 3). Whereas, combination of Mdm2 knockdown
and estrogen treatment additively decreased the ERα protein level (Figure 26B, compare lanes 3
and 4). Interestingly, in the vector control cell line the basal level of the ERα protein was much
lower than in the mdm2 shRNA-containing cell line (Figure 26B, compare lanes 1 and 5). But
regardless of that, doxycycline treatment in the vector control cell line did not affect the ERα
protein level as it did in the mdm2 shRNA-containing cell line (Figure 26B, compare lanes 1 and
2, and lanes 5 and 6).
In conclusion, we observed that induction of the mdm2 shRNA expression effectively
reduced the Mdm2 protein level in the MCF-7 cells both in the absence and in the presence of
the estrogen treatment. Furthermore, the decrease in the Mdm2 protein resulted in a robust
increase in the p21 protein level. However, since the p53 protein level did not change after the
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Mdm2 knockdown, it is possible that the increase in the p21 protein was partially p53independent. In fact, the Mdm2 protein is known to regulate p21 degradation in a p53independent manner by directly targeting p21 to the proteasome (Jin et al. 2003, Xu et al. 2010,
Zhang Z. et al. 2004b). Importantly, these results suggest that the estrogen-mediated cell
proliferation occurred though p21 inhibition by Mdm2.

Figure 26: Assessment of the Mdm2 protein knockdown by shRNA in the absence and in the
presence of an estrogen treatment in the MCF-7 cells. Clonal MCF-7 cell lines with mdm2
shRNA (151656 clone C4) or control vector were treated with (A) 2 µg/ml doxycycline for six
days or (B) 2 µg/ml doxycycline for three days followed by 10 nM estrogen (E2) for five days in
the presence of doxycycline. Mdm2, p53, p21, ERα and Actin protein levels from whole cell
lysates were analyzed by Western blot.
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Because we observed that the Mdm2 knockdown in the presence of estrogen robustly
increased the p21 protein level, we hypothesized that after the Mdm2 knockdown the cells would
lose their proliferative activity in the presence of estrogen. Therefore, we examined if the Mdm2
knockdown had any effect on the breast cancer cell proliferation in the presence of estrogen. We
observed that Mdm2 down-regulation repressed cell proliferation both in the absence and in the
presence of the estrogen treatment (Figure 27A, mdm2 shRNA). While in the vector control cell
line, doxycycline treatment did not significantly affect the cell proliferation in the absence or in
the presence of estrogen (Figure 27A, vector). Importantly, by determining the fold change in the
cell number under the different conditions, we observed that while the estrogen treatment
increased the cell proliferation by 2.8 fold, when Mdm2 was knocked down the increase in the
estrogen-mediated cell proliferation was only by 1.9 fold. Therefore, these results suggest that
Mdm2 was required not only for the endogenous cell proliferation (in the absence of estrogen),
but specifically for the estrogen-stimulated cell proliferation. In addition, since the knockdown of
Mdm2 decreased the number of cells, it was important to determine if the decrease in the cell
number was due to cell death or due to cell proliferation inhibition. Cell viability assay,
determined by the assessment of the cell membrane integrity, showed that the cells remained
viable after the Mdm2 knockdown both in the absence and in the presence of estrogen (Figure
27B). Therefore, we concluded that the decrease in the cell number after the Mdm2 knockdown
was due to inhibition of cell proliferation and not due to an increase in cell death.
In conclusion, in agreement with our hypothesis these results suggest that the estrogenmediated cell proliferation requires Mdm2 and, in turn, Mdm2 over-expression in the presence of
estrogen inhibits the cell cycle regulator p21. And consecutively, this process can culminate in
uncontrolled cell proliferation in the presence of estrogen.
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Figure 27: The estrogen-mediated MCF-7 cells proliferation was inhibited by the Mdm2
knockdown. MCF-7 cells carrying control vector and clonal MCF-7 cell line with mdm2 shRNA
(151656 clone C4) were treated with 2 µg/ml doxycycline for three days to induce shRNA
expression, followed by 10 nM estrogen (E2) for five days in the presence of doxycycline. 10,000
cells were seeded at beginning of treatments. Number of cells (A) and cell viability based on
membrane permeability (B) were determined by Guava Viacount assay at the end of the
treatments.
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Since the MCF-7 cells did not die after the Mdm2 knockdown while the p21 protein level
increased dramatically, we hypothesized that the decrease in the cell number was due to a change
in the cell cycling during the estrogen-mediated cell proliferation. To examine the effect of
estrogen, throughout the study estrogen treatments were carried out on cells that were grown in
otherwise steroids-depleted medium. Therefore, when estrogen was not added to the medium the
cells proliferated very slowly. And in fact, by FACS analysis we observed that the cell cycle
distribution included a high percent of cells in the G1 phase and a low percent of cells in the S
phase (data not shown). In the presence of estrogen, however, the cell proliferation rate increased
dramatically and the percent of cells in the S phase increased (data not shown).
When the cell cycle profile was examined after the Mdm2 knockdown in the presence of
estrogen, we saw that there was a significant increase in the percent of cells in the G1 phase and
a significant decrease in the percent of cells in the S phase (Figure 28, mdm2 shRNA). While in
the vector control cell line, the percent distribution did not change after the doxycycline
treatment (Figure 28, vector).
In conclusion, this result suggests that Mdm2 knockdown inhibited the estrogen-mediated
MCF-7 breast cancer cells proliferation by slowing the cells down in the G1 to S transition.
Importantly, this result implies that in the presence of estrogen Mdm2 over-expression inhibits
the p21 protein and thus allows the proliferating cells to bypass the G1 checkpoint.
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Figure 28: In MCF-7 cells, Mdm2 knockdown in the presence of estrogen inhibited the cell
cycle transition at the G1 to S phases of the cell cycle. MCF-7 cells carrying control vector and
clonal MCF-7 cell line carrying the mdm2 shRNA (151656 clone C4) were treated with 2 µg/ml
doxycycline for three days to induce shRNA expression, followed by 10 nM estrogen (E2) for five
days in the presence of doxycycline. The percent of cells in the different cell cycle phases was
determined by fluorescence activated cell sorting (FACS).
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Estrogen is known to inhibit apoptosis in the MCF-7 breast cancer cells by up-regulating
the expression of the anti-apoptotic protein Bcl-2 (Perillo et al. 2000). Though we did not
observe any increase in cell death after the Mdm2 knockdown in the presence of estrogen, we
wanted to determine if decreasing the levels of the Mdm2 protein will affect the estrogenmediated Bcl-2 expression. We hypothesized that Mdm2 over-expression in the presence of
estrogen may be important for the estrogen-mediated signaling toward Bcl-2 over-expression.
Interestingly, we observed that following Mdm2 knockdown in the presence of estrogen,
estrogen could no longer induce Bcl-2 expression to the same extent as it did in the presence of
Mdm2 (Figure 29, compare lanes 1-3-4). The Bcl-2 protein level also somewhat decreased after
doxycycline treatment in the vector control cell line (Figure 29, compare lanes 7 and 8), but the
decrease was not as striking as it was in the mdm2 shRNA-containing cell line (determined by
relative quantification of bands intensities with the ImageJ software, data not shown).
Doxycycline belongs to a well-known and widely used type of antibiotics, the tetracyclines
(Smilack 1999). The bacteriostatic activity of tetracyclines lies in their capacity to inhibit protein
synthesis. Because of the similarity between the prokaryotic protein synthesis machinery and that
of eukaryotic mitochondria, tetracyclines are also able to interfere with the mitochondrial protein
synthesis in the mammalian cells. Therefore, doxycycline, when used at high concentrations, can
induce growth arrest and/or cell death (Saikali and Singh 2003). In fact, we observed that using
higher concentrations of doxycycline appeared to be cytostatic to the MCF-7 cells (data not
shown). And perhaps even at the lower concentrations of doxycycline, where the cell
proliferation was not significantly inhibited, the expression of the mitochondrial proteins was
affected. And therefore, doxycycline treatment reduced the Bcl-2 protein level in the vector
control cell line.
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In conclusion, this result suggests that since the estrogen-mediated up-regulation of the
anti-apoptotic Bcl-2 protein expression was blocked by the Mdm2 knockdown, the overexpression of Mdm2 in the presence of estrogen is important for the estrogen-mediated induction
of Bcl-2 expression and thus inhibition of apoptosis.

Figure 29: In MCF-7 cells, the estrogen-mediated up-regulation of the anti-apoptotic Bcl-2
protein was inhibited by the Mdm2 knockdown. MCF-7 cells carrying control vector and clonal
MCF-7 cell line with mdm2 shRNA (151656 clone C4) were treated with 2 µg/ml doxycycline for
three days to induce shRNA expression, followed by 10 nM estrogen (E2) for five days in the
presence of doxycycline. Western blot analysis of Bcl-2 and Actin protein levels from whole cell
lysates.
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In the following experiment we compared the Mdm2 knockdown and the DNA damaging
drug etoposide with respect to their effects on the MCF-7 cells proliferation in the presence of
estrogen. Earlier in this study we observed that DNA damage induced by etoposide treatment
inhibited MCF-7 cells proliferation by inducing cell cycle inhibition in the G2/M checkpoint. In
turn, we observed that the Mdm2 knockdown in the presence of estrogen repressed MCF-7 cells
proliferation by inhibiting the cell cycle transition at the G1 checkpoint. Therefore, we
hypothesized that combination of Mdm2 knockdown and etoposide treatment would additively
inhibit MCF-7 cells proliferation in the presence of estrogen.
By Western blot analysis of the cellular protein levels, we saw that etoposide slightly
increased the Mdm2 protein level and robustly increased the p53 and the p21 protein levels
(Figure 30A, compare lanes 1 and 2). mdm2 shRNA induction decreased the Mdm2 protein
level, while the level of the p53 protein did not change (Figure 30A, compare lanes 1 and 3). In
agreement with earlier results, we observe that though the p53 protein expression did not
increase upon Mdm2 knockdown, the p21 protein level increased (Figure 30A, compare lanes 1
and 3). Importantly, when etoposide treatment and Mdm2 knockdown were combined, the p21
protein level became even higher than in the etoposide treatment alone samples, while there was
no further increase in the p53 protein level (Figure 30A, compare lanes 2 and 4). In contrast, in
the vector control cell line when etoposide treatment and Mdm2 knockdown were combined, the
p21 protein level was not different than when only the etoposide treatment was carried out
(Figure 30A, compare lanes 6 and 8).
In agreement with our hypothesis, we observed that the estrogen-mediated MCF-7 cells
proliferation was similarly inhibited by both etoposide treatment and Mdm2 knockdown (Figure
30B). Etoposide treatment caused a G2/M cell cycle arrest-like state and the Mdm2 knockdown
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induced a G1 arrest-like state (Figure 30C). Furthermore, combination of the Mdm2 knockdown
and etoposide treatment additively inhibited cell proliferation (Figure 30B). Interestingly, when
Mdm2 was knocked down, the G2/M population in the etoposide treated cells decreased and the
cells appeared to remain arrested in the G1 phase (Figure 30C).
In conclusion, we observed that Mdm2 knockdown in combination with etoposide
treatment additively inhibited MCF-7 cells proliferation in the presence of estrogen. And
importantly, we concluded that this inhibition in cell proliferation was mediated by the p21
protein since the additive inhibition of cell proliferation correlated with an additive increase in
the p21 protein level.
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Figure 30: Mdm2 knockdown in combination with etoposide treatment additively inhibited
MCF-7 cells proliferation in the presence of estrogen. Clonal MCF-7 cells with mdm2 shRNA
(151656 clone C4) or vector control were treated with 2 µg/ml doxycycline for three days,
followed by 10 nM estrogen (E2) for five days and 50 μM etoposide (ETOP) for 48 hours in the
presence of doxycycline. (A) Western blot analysis of Mdm2, p53, p21 and Actin protein levels
from whole cell lysates. (B) 10,000 cells were seeded. The number of cells at the end of the
treatment was determined by the Guava Viacount assay. (C) The percent of cells in the different
cell cycle phases was determined by fluorescence activated cell sorting (FACS). (In B and C, the
vector control cell line was omitted for clarity. No change was observed after Mdm2
knockdown).
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In the experiment described above, we observed that etoposide treatment and Mdm2
knockdown additively inhibited MCF-7 cells proliferation. Interestingly, combination of Mdm2
knockdown with chemotherapeutic agents or radiation therapy has been described to exhibit an
additive effect on tumor growth both in vitro and in vivo (Liu T. G. et al. 2004, Wang H. et al.
2001, Zhang Z. et al. 2004c). Therefore, we wanted to determine if the additive inhibition of
MCF-7 cells proliferation occurred because the etoposide-mediated inhibition of cell
proliferation was improved by the Mdm2 knockdown, and thus the two mechanisms are part of
the same pathway. We hypothesized, however, that since Mdm2 knockdown induced a G1
arrest-like state while etoposide treatment induced a G2/M arrest-like state, then the two events
are involved in two independent pathways that regulate cell proliferation. And therefore, the
etoposide-mediated inhibition of MCF-7 cells proliferation will not be augmented by the Mdm2
knockdown.
To test this hypothesis, in the following experiment first we treated the MCF-7 cells with
doxycycline for six days to induce Mdm2 knockdown and then we exposed the cells to
increasing concentrations of etoposide for an additional 48 hours while continuing the
doxycycline treatment. Importantly, after the six days of Mdm2 knockdown the cells were
counted and equal numbers of cells were seeded before the etoposide treatment. And therefore,
the difference in the cell number that occurred because of the Mdm2 knockdown was not visible
in this experiment. In support of our hypothesis, we observed that the etoposide-mediated
inhibition of cell proliferation was not augmented by the Mdm2 knockdown (Figure 31),
suggesting that cells with the Mdm2 protein down-regulated did not become more sensitive to
the etoposide treatment.
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Importantly, the result of this experiment suggests that Mdm2 knockdown and DNA
damage induced by etoposide target two independent but parallel pathways that control cell
proliferation. Furthermore, this result also suggests that Mdm2 does not play a role in the
etoposide-mediated inhibition of cell proliferation and vice versa.

Figure 31: In MCF-7 cells, etoposide-mediated inhibition of cell proliferation was not
augmented by the Mdm2 knockdown. Clonal MCF-7 cells with mdm2 shRNA (151656 clone
C4) were treated with 2 µg/ml doxycycline for six days. Then equal number of cells were seeded
and treated with increasing concentrations of etoposide (25, 50, 100, 200 µM) for 48 hours in
the absence or in the presence of 2 µg/ml doxycycline. Cell proliferation was determined by the
MTT colorimetric assay, which measures the mitochondrial activity of the cells.
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We also investigated if the estrogen-mediated cell proliferation occurred due to inhibition
of the p53 pathway by Mdm2. We hypothesized that if the p53 pathway was inhibited by
estrogen treatment during the estrogen-mediated cell proliferation then blocking the p53 pathway
would further augment the estrogen-mediated effect. Therefore, in the following experiment we
examined how the p53 knockdown affected cell proliferation in the presence of estrogen. We
reasoned that if the p53 pathway was indeed inhibited during the estrogen-mediated cell
proliferation, than p53 knockdown would release this inhibition and that, in turn, will allow for
even greater increase in the cell proliferation in the presence of estrogen.
Following expression of the p53 shRNA in the MCF-7 cells, we observed a modest
reduction in both p53 and p21 protein levels (Figure 32A, compare lanes 1 and 2). Interestingly,
similar to our earlier observations estrogen treatment increased the level of the p53 protein while
the level of the p21 protein decreased (Figure 32A, compare lanes 1 and 3). By Western blot
analysis it appeared that expression of the p53 shRNA in the presence of estrogen decreased the
p53 protein level only slightly (Figure 32A, compare lanes 3 and 4), but quantification of the
bands intensities by the ImageJ software showed that the p53 protein level decreased by 50%
after the p53 shRNA induction in the presence of estrogen (data not shown). In the vector control
cell line we observe that there was no change in the p53 and p21 protein levels after doxycycline
treatment in the absence or in the presence of estrogen (Figure 32A, compare lanes 5-8). While
similar to the p53 shRNA cell line, in the vector control cell line estrogen treatment decreased
the protein level of p21 (Figure 32A, compare lanes 5-8). Interestingly, we observed that the
estrogen-mediated increase in the Mdm2 protein level was not inhibited when the p53 protein
was knocked down (Figure 32A, compare lanes 1-3-4). This suggests that the estrogen-mediated
increase in the Mdm2 protein was not dependent on p53. In support of this observation, it has
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been described earlier that estrogen can induce Mdm2 expression in the T-47D cell line, a breast
cancer cell line that carries a mutant p53 (Hu et al. 2007).
With regards to the MCF-7 cells proliferation, after p53 knockdown we observed that
there was a slight increase in the cell proliferation, but the increase was not significant, as the p
value was greater than 0.05 (Figure 32B). Similarly, p53 knockdown in the presence of estrogen
did not induce any further increase in the estrogen-mediated cell proliferation (Figure 32B). This
result suggests that inhibition of the basal activity of the p53 protein did not affect the estrogenmediated cell proliferation.
In conclusion, in this experiment we observed that estrogen treatment robustly increased
MCF-7 cells proliferation, while no further increase in cell proliferation was achieved when the
p53 protein was knocked down. This observation suggests that estrogen signaling promoted cell
proliferation independently of p53 and that other pathways were affected during this process.
Importantly, since the estrogen’s impact on cell proliferation strongly depended on Mdm2, this
result also suggests that a portion of the Mdm2 influence was p53-independent.
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Figure 32: In MCF-7 cells, p53 knockdown did not affect the estrogen-mediated up-regulation
of cell proliferation. MCF-7 cells carrying control vector or clonal MCF-7 cell line with p53
shRNA (p53 2120 clone D11) were treated with 2 µg/ml doxycycline for three days to induce
shRNA expression, followed by 10 nM estrogen (E2) for five days in the presence of doxycycline.
10,000 cells were seeded at beginning of treatments. (A) Western blot analysis of p53, Mdm2,
p21 and Actin protein levels from whole cell lysates. (B) Number of cells was determined by
Guava Viacount assay at the end of the treatments.
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3.2.3 Discussion
In response to estrogen, ERα induces transcription of target genes (e.g. myc, cyclin-D1,
and bcl-2) to regulate cell growth and survival (Pearce and Jordan 2004). The mitogenic effects
of estrogen are largely attributed to its ability to increase the expression of key cell cycle
regulatory genes, which allow for G1 to S progression during the cell cycle (Prall et al. 1997).
Importantly, we concluded that since the estrogen-mediated MCF-7 cells proliferation was
inhibited by Mdm2 knockdown, the Mdm2 protein over-expression was required for the
estrogen’s signaling during this process. Specifically, our data show that Mdm2 knockdown led
to an increase in the protein level of the cell cycle inhibitor, p21. The p21 cyclin-dependent
kinase inhibitor is a cell-cycle regulator that inhibits the G1 to S phase transition. This suggests
that Mdm2 inhibits p21 during cell cycle progression in the presence of estrogen and that
estrogen robustly blocks this proliferative checkpoint pathway through the up-regulation of
Mdm2.
To confirm this hypothesis it will be important to carefully examine the roles that Mdm2
and p21 play during the estrogen-mediated cell proliferation. To achieve that, one option would
be to knockdown Mdm2 and p21 simultaneously. Since the Mdm2 knockdown alone leads to
p21 protein increase, which, in turn, blocks the estrogen-mediated cell proliferation, then
simultaneously knocking down p21 will allow the cells to continue to proliferate in the presence
of estrogen even when the Mdm2 is knocked down.
Since p21 is a transcriptional target of p53, initially we hypothesized that Mdm2 was
inhibiting the p21 protein by negatively regulating p53. In both MCF-7 and ZR75-1 breast
cancer cell lines, the Mdm2 knockdown did not increase the p53 protein level, while the
transcription of the p53 target gene p21 increased. Therefore, it is important to note that down-
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regulating Mdm2 in ERα+ breast cancer cells can functionally activate their wild-type p53
protein. These results suggest that estrogen uses an Mdm2-mediated pathway to provoke cell
proliferation and that this pathway requires both p53-dependent and -independent signal
transduction pathways.
To directly test if p53 is targeted during the estrogen-mediated Mdm2 over-expression
and MCF-7 cells proliferation, we knocked down p53 by shRNA in the presence of estrogen. We
observed, however, that while estrogen treatment robustly increased the MCF-7 cells
proliferation, there was no further increase in cell proliferation when the p53 protein was
knocked down. This observation suggests that the influence of Mdm2 during the estrogenmediated cell proliferation was p53-independent. Importantly, Mdm2 has been shown to regulate
p21 independently of p53. This occurs by Mdm2 binding to p21, inducing a conformational
change in p21 and thus increasing p21’s interaction with the C8 proteasome subunit (Jin et al.
2003, Xu et al. 2010, Zhang Z. et al. 2004b). Therefore, it is possible that estrogen regulates cell
cycle progression by inducing Mdm2 over-expression, which, in turn lead to p21 inhibition, but
all this occurs in a p53-independent manner.
Interestingly, we observed that the inhibition in the estrogen-mediated cell proliferation
after the Mdm2 knockdown was comparable to that achieved by the DNA damaging agent
etoposide. However, it appeared that the inhibition was achieved through two different pathways,
where Mdm2 regulated the G1 checkpoint, while etoposide regulated the G2/M checkpoint.
Furthermore, combination of etoposide treatment and Mdm2 knockdown additively inhibited cell
proliferation. Taken together, these data suggest that it is important to consider Mdm2 as a target
in the development of future breast cancer therapies.
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In addition, we also observed that Mdm2 knockdown decreased the estrogen-mediated
anti-apoptotic Bcl-2 protein expression. We also observed that the up-regulation in the Bcl-2
expression in the presence of estrogen correlated with inhibition of the pro-apoptotic Puma
protein expression. Taken together, these results suggest that Mdm2 may play a role in the
estrogen-mediated cell survival, which may be required during the high rate of cell proliferation
that is induced by estrogen.

Summary of conclusions
1) Since the Mdm2 knockdown blocked the estrogen-mediated MCF-7 cells proliferation, the
Mdm2 over-expression was required for the estrogen-mediated effect.
2) During the estrogen-induced cell proliferation Mdm2 over-expression in the presence of
estrogen blocked p21 and allowed the cells to bypass the G1 checkpoint.
3) The p53 knockdown did not potentiate the estrogen-mediated MCF-7 cells proliferation,
suggesting that other pathways were targeted by Mdm2 during the estrogen-mediated
signaling.
4) The estrogen-mediated up-regulation of the anti-apoptotic Bcl-2 protein was blocked by the
Mdm2 knockdown, suggesting that the estrogen-mediated Mdm2 over-expression may be
important for the estrogen-mediated inhibition of apoptosis.
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Figure 33: A model illustrating that Mdm2 plays a central role in the estrogen-mediated breast
cancer cell proliferation. The data suggest that Mdm2 inhibited p21 expression both via and
independently of p53 and thus promoted the estrogen-mediated cell proliferation. In turn, this
suggests that the inhibition of the p21 protein allowed the cells to bypass the G1 checkpoint
during the estrogen-mediated cell proliferation. In addition, we observed that Mdm2 was
required for the estrogen-mediated Bcl-2 up-regulation which, in turn, correlated with Puma
down-regulation. The data suggest that Mdm2 affected several pathways during the estrogeninduced breast cancer cell proliferation, which are associated with the regulation of the G1
checkpoint and cell survival.
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3.3 Studying the role of Mdm2 in cell proliferation in 3D culture (soft agar and matrigel).
3.3.1 Introduction
Conducting experiments in 3D cultures, that closely resemble the environmental
conditions found in tissues, can better recapitulate the behavior of cancer cells in vivo. In
addition to examining the role of the Mdm2 protein in cell proliferation in the 2D cultures, we
also studied the function of the Mdm2 protein in breast cancer cell proliferation in soft agar (3D
cultures). Anchorage-independent colony formation of cultured cells in soft agar is often
associated with in vivo malignancies and has been used as a marker for cellular transformation
(Pavelic et al. 1980, Wada et al. 1984). MCF-7 cells have been shown to depend on estrogen for
colony formation in soft agar (Stevens and Meech 2006). Furthermore, over-expression of Mdm2
in MCF-7 cells affords a growth advantage in soft agar in the presence of estrogen (Saji et al.
1999). Therefore, in the following experiments, we examined the effect of Mdm2 knockdown on
anchorage-independent MCF-7 cell growth in soft agar in the presence of estrogen.
In addition to studying the role of Mdm2 in the anchorage-independent cell growth, we
also examined the role of Mdm2 in cell growth in matrigel (3D cultures). The female breast is
composed of several major duct systems, each comprising of numerous lobules. A lobule
consists of a terminal branch-like system of lobular cells, which empty into the ducts. A cross
section of the duct reveals that it has a hollow lumen, which is lined by an inner layer of
epithelial cells. In ductal carcinoma in situ (DCIS), this inner layer of epithelial cells continues to
proliferate and eventually fills in the lumen (Wiechmann and Kuerer 2008). The matrigel
consists of a gelatinous protein mixture that resembles the complex extracellular environment
found in many tissues. The growth of normal mammary epithelial cells in matrigel results in
formation of polarized, growth-arrested acini-like spheroid structures that recapitulate several
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aspects of glandular architecture in vivo. Mammary tumor cells, however, continue to proliferate
into disorganized masses (Cordon-Cardo et al. 1994). Since MCF10A cells are considered to be
normal immortalized mammary epithelial cells, we compared MCF-7 breast cancer cells to the
MCF10A cells. Once we confirmed the different morphologies that MCF10A and MCF-7 cell
lines form in matrigel, we began to determine if the Mdm2 knockdown affected the MCF-7 cells
growth in matrigel.

Figure 34: Examining whether the Mdm2 protein controls the estrogen-mediated cell
proliferation in 3D culture. In addition to examining the role of the Mdm2 protein in the 2D
cultures, we also studied the function of the Mdm2 protein in the estrogen-mediated breast
cancer cell proliferation in soft agar (anchorage-independent growth) and in matrigel (mass
formation).
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3.3.2 Results
To study the role of the Mdm2 protein in the MCF-7 cells grown in soft agar in the
presence of estrogen, in the preliminary experiment that is described below, we examine how the
MCF-7 cells behaved in soft agar in the absence and in the presence of estrogen. We observed
that MCF-7 cells, when grown for two weeks in growth medium containing complete FBS,
formed large colonies in soft agar (Figure 35A, complete FBS). Interestingly, the MCF-7 cells
did not form colonies in medium that was depleted of steroids (Figure 35A, charcoal-stripped
FBS). In fact, higher magnification revealed that the cells did not grow in soft agar in the
absence of steroids (Figure 35B, (-E2)). In the presence of estrogen, the MCF-7 cells proliferated
and formed large and multicellular colonies in soft agar, though the colonies were not as big as
the ones formed in growth medium with complete FBS (Figure 35A, compare complete FBS and
charcoal-stripped FBS (+E2)).
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Figure 35: Estrogen was required for the MCF-7 colony formation in soft agar. MCF-7 cells
were grown for two weeks in soft agar. The agar was mixed and covered with different growth
media: growth medium with complete FBS, growth medium with charcoal-stripped FBS and
growth medium with charcoal-stripped FBS and 10 nM estrogen. Representative images of
colonies formed by the MCF-7 cells in soft agar under the different growth media conditions are
shown. 40x magnification (A) and 100x magnification (B).
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In the following experiment, we wanted to determine if the Mdm2 protein was required
for the estrogen-mediated colony formation by the MCF-7 cells in soft agar. We hypothesized
that since the Mdm2 protein was required for the estrogen-mediated cell proliferation in the 2D
culture, then, similarly, the Mdm2 protein will be required for the cell growth in the 3D culture.
To carry out this experiment, initially, we grew the cells in the 2D culture in the presence of
complete growth medium and doxycycline to knockdown the expression of Mdm2. After six
days of doxycycline treatment, we seeded the cells in soft agar, which contained growth medium
supplemented with charcoal-stripped FBS, estrogen and doxycycline (for continuous Mdm2
knockdown). After growing the cells in soft agar for two weeks, we counted the large colonies
that formed in the absence and in the presence of the Mdm2 knockdown. Importantly, in order to
determine the effect of the mdm2 shRNA expression on the MCF-7 cells growth in soft agar, in
the Mdm2 knockdown samples only the GFP expressing colonies were counted.
We observed that upon the Mdm2 knockdown, the number of the large and multicellular
colonies decreased dramatically (Figure 36A and Figure 36B, mdm2 shRNA). Whereas, in the
vector control cell line, doxycycline treatment had no effect on the colony formation by the
MCF-7 cells in soft agar in the presence of estrogen (Figure 36A and Figure 36B, vector).
Evidently, in the previous experiment, we observed that in the presence of estrogen the MCF-7
cells form colonies of an average size of 50 µm (Figure 35B). Importantly, the Mdm2
knockdown dramatically decreased the number of colonies of 50 µm in size or larger that formed
in the presence of estrogen in soft agar (Figure 36B). This experiment shows that Mdm2
knockdown inhibited large colony formation of MCF-7 cells in soft agar in the presence of
estrogen, and that Mdm2 is required for the estrogen-mediated anchorage-independent MCF-7
cell growth.
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Figure 36: Mdm2 knockdown inhibited large (multicellular) colony formation when MCF-7
cells were grown in soft agar in the presence of estrogen. MCF-7 cells were grown on plates
(2D) for six days in the presence of 2 µg/ml doxycycline in growth medium with complete FBS.
The cells were then washed, trypsinized and mixed with agar in growth medium containing
charcoal-stripped FBS, 10 nM estrogen and 2 µg/ml doxycycline. Cells were grown in the agar
for two weeks. (A) Representative images of colonies that MCF-7 cells formed in soft agar in the
absence and in the presence of mdm2 shRNA induction (40x magnification). (B) The number of
colonies (50 µm in size or larger) was determined by counting the colonies on the dissecting
fluorescent microscope. In the mdm2 shRNA samples only the GFP expressing colonies were
counted. Averages of two independent experiments are shown. Each experiment was done in
three replicates. The p-value was determined by the Student t-test.
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To study the role of the Mdm2 protein in the MCF-7 cells grown in matrigel, in the
preliminary experiment that is described below, we examine how the MCF-7 cells behaved in the
3D matrigel culture. In line with the published work from the Bissell laboratory (Kenny et al.
2007, Lu et al. 2002), we observed that the MCF-7 breast cancer cells form disorganized masses
of different sizes in the matrigel (Figures 37A and 37B, MCF-7). Whereas the MCF10A cells,
which are considered to be normal breast epithelial cells, formed organized and defined acini
(Figures 37A and 37B, MCF10A). The intermediate masses that were formed by the MCF-7
cells somewhat resembled the MCF10A acini structures (Figures 37A, MCF-7 and MCF10A).
However, a cross section of the intermediate MCF-7 mass structure showed that upon Mdm2
knockdown the lumen remain filled with cells (Figure 37C, PI staining).

110

Figure 37: Assessment of the MCF-7 and MCF10A cells growth and morphology in matrigel.
MCF-7 and MCF10A cells were grown in matrigel for three weeks, followed by fixation in
formaldehyde and propidium iodide staining. (A) MCF-7 and MCF10A breast cells
morphologies in matrigel (3D culture). (B) Confocal analysis of MCF-7 and MCF10A cells
morphologies. Propidium iodide staining is shown. (C) Confocal analysis of MCF-7 cells grown
in matrigel for three weeks in the absence or presence of 2 µg/ml doxycycline. Propidium iodide
staining and GFP expression are shown. Representative images of cells from two independent
experiments are shown.
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In the following experiment, we wanted to determine what role the Mdm2 protein plays
during the MCF-7 cells growth in matrigel. We hypothesized that since the Mdm2 protein was
required for the estrogen-mediated cell proliferation in the 2D culture, then, similarly, the Mdm2
protein will be required for the MCF-7 cells growth in the matrigel. In the experiment described
below, the cells were grown in the presence of estrogen in otherwise steroid-depleted growth
medium. We observed that the MCF-7 cells grown in matrigel formed masses of three different
sizes: large, intermediate and small (Figure 38A). Only a small percent of the structures (about
13%) had an intermediate mass size, which somewhat resembled the MCF10A acini structures
(Figure 38A and 38B, mdm2 and vector control, no shRNA induction). While about 44-46% of
the structures were either large or small (Figure 38B, mdm2 and vector control, no shRNA
induction). Importantly, the Mdm2 knockdown decreased the number of the large structures and
increased the number of the small structures that MCF-7 cells formed in the matrigel (Figure
38B, mdm2). While in the vector control cell line doxycycline treatment did not affect the
distribution of the different mass morphologies (Figure 38B, vector).
In conclusion, this experiment showed that the Mdm2 protein was required for the large
mass formation by the MCF-7 cells in matrigel, suggesting that Mdm2 over-expression may play
a role in disorganized and invasive-like phenotypes of breast cancer cells.
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Figure 38: Mdm2 knockdown decreased the ability of the MCF-7 cells to form large masses in
the matrigel in the presence of estrogen. (A) MCF-7 cells, grown in matrigel for three weeks,
formed mass structures of three different sizes: large, intermediate and small. (B) MCF-7 cells,
grown in matrigel for three weeks in the presence of estrogen and in the absence or presence of
2 µg/ml doxycycline, were fixed and stained with propidium iodide. Masses of different sizes
(large, intermediate and small) were counted and presented as percent of the total population. A
total of about 300 structures were counted. In the mdm2 shRNA samples only the GFP
expressing masses were counted. Averages of three independent experiments are shown. The
significance in the percent change of large and small structures was determined by the student ttest (p < 0.05).
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3.3.3 Discussion
In the 2D culture, we have observed that Mdm2 protein levels become elevated in the
presence of estrogen and that Mdm2 is required for the estrogen-mediated MCF-7 breast cancer
cells proliferation. In soft agar (3D culture), our experimental observations confirmed that the
MCF-7 cells acquired anchorage-independent growth advantage when grown in the presence of
estrogen (Stevens and Meech 2006) and that this growth was dependent on Mdm2 (Saji et al.
1999).
When grown in matrigel (3D culture), the MCF-7 cells do not form acini, but exhibit a
mass-like morphology (Kenny et al. 2007). This phenotype recapitulates the ductal carcinoma in
situ (DCIS) breast cancer type that is characteristic of a filled in lumen appearance. Interestingly,
we observed that the cell masses appeared to be of three different sizes: small, intermediate and
large. The large masses slightly resembled the grape-like morphology, which is characteristic of
the invasive and aggressive breast cancer cells (Kenny et al. 2007). This suggests that the MCF-7
cells exhibit a somewhat intermediate aggressive breast cancer cell phenotype in matrigel. The
intermediate size masses were similar in size and shape to the acini that the normal mammary
epithelial MCF10A cells form in matrigel. But the masses formed by the MCF-7 cells had a
filled lumen as opposed to the MCF10A acini that had a hollow lumen. When we knocked down
Mdm2 in the MCF-7 cells grown in matrigel, we observed that the large mass-like structures
were replaced with smaller structures, suggesting that Mdm2 is important for the MCF-7 cells
proliferation in matrigel. Furthermore, this observation also suggests that Mdm2 may be
important for the invasive behavior of breast cancer cells. Therefore, additional studies on the
role of the Mdm2 protein in the aggressive metastatic cells in the presence of estrogen are
needed.
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Summary of conclusions
1) Mdm2 is required for large colony formation in soft agar in the presence of estrogen,
suggesting that Mdm2 is important for the estrogen-mediated anchorage-independent cell
growth.
2) Mdm2 is required for the large mass formation in matrigel, suggesting that Mdm2 overexpression promotes disorganized and invasive-like phenotypes in breast cancer cells.

Figure 39: Mdm2 plays an important role in the estrogen-mediated MCF-7 cells proliferation
in 3D culture. In addition to playing a pivotal role during the estrogen-mediated cell
proliferation in 2D culture, the Mdm2 protein is required for large colony formation in soft agar
and large mass formation in matrigel.
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CHAPTER 4:
FUTURE DIRECTIONS
AND
PRELIMINARY DATA
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4.1 Introduction
Our major conclusion from this study is that the estrogen-mediated MCF-7 breast cancer
cell proliferation requires Mdm2. This was illustrated in a few key experiments. We observed
that the increase in cell proliferation in the presence of estrogen correlated with an increase in the
Mdm2 protein level. In turn, Mdm2 knockdown inhibited cell proliferation in the presence of
estrogen. Importantly, this inhibition in cell proliferation was associated with inhibited transition
through the G1 checkpoint.
To clarify our findings, this project could be expanded by addressing the following
questions:
1. Determine if a p53-independent role of Mdm2 is required for the stimulation of the estrogenmediated breast cancer cell proliferation.
2. Determine if MdmX plays a role in the estrogen-mediated breast cancer cell proliferation.
3. Determine the roles of Mdm2 and MdmX in drug-sensitivity of breast cancer cells in the
presence of estrogen.
4. Determine the downstream pathway(s) targeted by Mdm2 in the presence of estrogen.
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4.2 Determine if a p53-independent role of Mdm2 is required for the stimulation of the
estrogen-mediated breast cancer cell proliferation.
Mdm2 is a major known inhibitor of the p53 tumor suppressor. Mdm2 over-expression
often occurs in human tumors that retain a wild-type p53 genotype (Landers et al. 1994,
Momand et al. 1998). The Mdm2 protein has been shown to be over-expressed in the ERα+
breast cancers (Bueso-Ramos et al. 1996, Hori et al. 2002, Marchetti et al. 1995) and to be
associated with worse survival of patients (Turbin et al. 2006). In turn, though the p53 gene is the
most commonly mutated gene in human cancers (Vogelstein et al. 2000), mutations in the p53
gene occur rarely in breast cancers (20-30%) (Caleffi M 1994, Coles et al. 1992, Hartmann et al.
1997, Pharoah et al. 1999). Considering these correlations, we hypothesized at the beginning of
this study that in the ERα+ breast cancers, the p53 activity may be suppressed through the
estrogen-mediated over-expression of Mdm2.
Therefore, a great majority of our initial experiments focused on examining the effects of
estrogen-mediated Mdm2 over-expression on the p53 pathway. We observed that estrogen
robustly increased the Mdm2 protein levels in the MCF-7 breast cancer cells. Although estrogen
treatment inhibited the transcription of several p53 target genes, the p53 protein level, nuclear
localization and p53 interaction with the chromatin were not affected by estrogen. Interestingly,
other groups have shown that ERα inhibits the p53 transcriptional activity by directly interacting
with the p53 protein on the chromatin (Liu G. et al. 2000, Sayeed et al. 2007). And in fact, a
sequential ChIP assay has demonstrated that ERα represses p53-mediated transcriptional
activation in human breast cancer cells by recruiting nuclear receptor co-repressors and histone
deacetylases (Konduri et al. 2010). These studies, however, did not address the role of Mdm2 in
this process.

118

Overall, our finding and other published studies suggest that estrogen may be using an
Mdm2-mediated pathway to provoke cell proliferation and this pathway may require the
inhibition of both p53-dependent and p53-independent signal transduction pathways. In the
future, we will carry out experiments to determine if a p53-independent role of Mdm2 is required
for the stimulation of estrogen-mediated breast cancer cell proliferation.
Importantly, we observed that the estrogen-mediated MCF-7 cell proliferation was
inhibited after Mdm2 knockdown, but was not affected by the p53 knockdown. This result
suggests that the inhibition of the p53 protein basal activity does not affect the estrogen-mediated
cell proliferation. Mdm2 knockdown by antisense oligonucleotides has been shown to inhibit cell
proliferation, increase p21 protein, and increase sensitivity to chemotherapeutic agents and
radiation in both MCF-7 (p53 wild-type) and MDA-MB-468 (p53 mutant, R273H) breast cancer
cells and xenografts (Wang H. et al. 2001, Zhang Z. et al. 2004c). This supports our hypothesis
that Mdm2 may promote cell proliferation and survival in a p53-independent manner. To
determine if Mdm2 over-expression stimulates cell proliferation in the presence of estrogen in a
p53-indepented manner, it is important to examine the role of Mdm2 in the presence of estrogen
in a breast cancer cell line with a mutant p53, for example, the T-47D cell line. This cell line is
ERα+, shows over-expression of Mdm2 in the presence of estrogen and has a mutant p53
(L194F). Our laboratory has begun to work on generating clonal T-47D cell lines with inducible
shRNA expression toward mdm2. Future experiments will focus on characterizing the cell lines
and determining if the effect of Mdm2 knockdown on estrogen-mediated cell proliferation in this
cell line would be similar to the one we observed in the MCF-7 cell line. In addition, to test if the
estrogen-mediated signaling via Mdm2 is p53-independent, it is important to examine if there is
a difference in estrogen-mediated cell proliferation in cells with up-regulated function of p53. By
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over-expressing a functional p53 in MCF-7 cells in the presence of estrogen it will be possible to
examine if the up-regulation in p53 can attenuate the estrogen-mediated cell proliferation.
In addition, since the knockdown of Mdm2 shows that Mdm2 is required for estrogenmediated cell proliferation, but it is not clear if Mdm2 is targeting p53 in this process, both p53
and Mdm2 should be targeted simultaneously. To achieve that, cell lines that carry inducible
shRNAs for both p53 and Mdm2 should be generated. To make sure there is an efficient
expression of both shRNAs in the same cells, the p53 and mdm2 shRNA-containing constructs
should be cloned into expression vectors with different selection and expression markers. If
indeed the inhibition in cell proliferation after Mdm2 knockdown is not due to activation of p53,
then cell proliferation will still be inhibited after simultaneous knockdown of Mdm2 and p53.
However, if we find out that the estrogen-mediated cell proliferation does not depended on p53,
it is also possible that the p53 family members (p63 and p73) are involved in this process.
Therefore, it is also important to determine if estrogen has any inhibitory functions with respect
to p63 or p73 proteins.
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4.3 Determine if MdmX plays a role in the estrogen-mediated breast cancer cell
proliferation.
Gene amplification and over-expression of MdmX, an Mdm2 homolog, have been
implicated in tumor development (Wade et al. 2010). Both Mdm2 and MdmX can bind the p53
protein and thus inhibit its activity (Toledo and Wahl 2007). Like Mdm2, the MdmX protein
directly inhibits p53 due to its ability to bind to the transactivation domain of p53 and, thus,
block the p53 transcriptional activity. But in contrast to Mdm2, MdmX is not under the
transcriptional control of p53. Although MdmX contains a RING finger domain, it does not
possess an E3 ubiquitin ligase activity. Mdm2 and MdmX form heterodimers through the
conserved C-terminal RING finger domains of the proteins. While both proteins can form
homodimers, heterodimers are preferentially formed. The heterodimer formation results in
reduced auto-ubiquitination of Mdm2 and increased p53 ubiquitination and degradation (Kostic
et al. 2006, Linke et al. 2008). Phosphorylation of MdmX plays a key role in its regulation and
promotes MdmX degradation in response to DNA damage, which, in turn, leads to p53
stabilization and activation (Okamoto et al. 2005).
We have observed that the Mdm2 protein is required for the estrogen-mediated
stimulation of breast cancer cells proliferation. Based on the literature, Mdm2 appears to
function in synergy with MdmX (Wade and Wahl 2009). Therefore, it is important to determine
if the MdmX protein plays a role in the estrogen-mediated breast cancer cells proliferation, and
whether the Mdm2 and the MdmX proteins function together during this process. Evidently, the
MCF-7 cells over-express MdmX due to genomic amplification (Danovi et al. 2004). Elevated
MdmX expression has been shown to cooperate with the oncogenic Ras to transform cells
(Danovi et al. 2004). Therefore, the MCF-7 cell line is a good candidate to examine the changes
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in the estrogen-mediated cell proliferation after mdmx knockdown in the presence of estrogen.
Notably, in the future experiments it will be important to determine how MdmX knockdown
affects cell proliferation and what happens to the MdmX protein level when the Mdm2 protein is
knocked down and vice versa.

4.3.1 Preliminary data
In our preliminary experiments, we have generated several MCF-7 cell lines (pools)
which contain doxycycline-inducible shRNA for mdmx. An example of MdmX knockdown
characterization in a clonal MCF-7 cell line with mdmx shRNA is shown below (Figure 40). We
observed that doxycycline addition for six days, in order to induce mdmx shRNA expression,
decreased the MdmX protein level (Figure 40, compare lanes 3 and 4), while in the vector
control cell line there was no change in the MdmX protein level (Figure 40, lanes 1 and 2). This
cell line will be used in future experiments to determine if MdmX plays a role in estrogenmediated breast cancer cell proliferation.

Figure 40: Characterization of the MCF-7 clonal cell line carrying the shRNA for mdmx.
MCF-7 cells with control vector or clonal MCF-7 cell line with mdmx shRNA (13023 clone D5)
were treated with 2 µg/ml doxycycline for six days. Western blot analysis of MdmX and Actin
protein levels from whole cell lysates.
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4.4 Determine the roles of Mdm2 and MdmX in drug-sensitivity of breast cancer cells in
the presence of estrogen.
Here, we propose that the roles of Mdm2 and MdmX in drug-sensitivity of breast cancer cells in
the presence of estrogen should be examined. Earlier, we observed that Mdm2 knockdown and
etoposide treatment additively inhibited the proliferation of the MCF-7 cells. Several studies
have shown that the Mdm2 knockdown can sensitize the breast cancer cells to chemotherapeutic
agents and radiation treatments (Bianco et al. 2005, Liu T. G. et al. 2004, Wang H. et al. 2001,
Zhang Z. et al. 2004c). Similarly, endogenous MdmX levels have been shown to affect the
sensitivity of breast cancer cells to anti-cancer agents (Lam et al. 2010). Therefore, we will
explore the strategy of targeting Mdm2 and MdmX by knockdown to increase the drug response
of breast cancer cells in the presence of estrogen.

4.4.1 Preliminary data
In our preliminary experiments, we began to examine the effects of the different drugs on
the MCF-7 breast cancer cells. We used drugs that differentially affect the MCF-7 cells:
etoposide, Mitomycin C (MC), and 10-decarbamoyl Mitomycin C (DMC). While etoposide is
known to induce DNA damage in a form of double strand breaks (van Maanen et al. 1988), MC
and DMC treatments result in various DNA adducts, intra- and inter-DNA cross-links (Paz et al.
2008). We observed that all three drugs inhibited the mitochondrial activity of the cells (Figure
41A, MTT assay). However, inhibition of mitochondrial activity can be interpreted as either
inhibition of cell proliferation or induction of cell death. The viability assay, which determines
cell membrane integrity, showed that the cell membrane integrity was disrupted after MC
treatment, but was not affected by etoposide or DMC treatments (Figure 41B).
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Figure 41: MCF-7 cells were differentially affected by etoposide, MC and DMC treatments.
MCF-7 cells were treated with 50 μM etoposide (ETOP), 10 μM Mitomycin C (MC), and 10 μM
10-decarbamoyl Mitomycin C (DMC) for 24, 48 and 72 hours. Graphs show averages and
standard errors of two independent experiments. (A) Mitochondrial activity (which can represent
both cell proliferation and cell death) was measured by the MTT assay. (B) Cell viability was
determined by the Guava Viacount assay (measures membrane integrity).
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The cell cycle distribution analysis determined by the FACS assay showed that etoposide
induced a G2/M cell cycle arrest (Figure 42, compare Untreated and ETOP). MC treatment
increased the percent of cells in the sub-G1 phase with a concomitant decrease in the percent of
cells in the G1 phase (Figure 42, compare Untreated and MC). This indicates that the MC drug
induced DNA fragmentation and that the cells were undergoing apoptosis. This is supported by
the observation that there were fewer cells with mitochondrial activity, as measure by the MTT
assay (Figure 42A), and that cells lost their membrane integrity (Figure 42B). Interestingly,
DMC treatment showed no change in cell cycle profile (Figure 42, compare Untreated and
DMC), though it induced the greatest level of cell death (Figure 42A and data not shown).
Recently, we have shown that the DMC drug kills cells through a p53-independent cell death
pathway which involves Chk1 down-regulation (Boamah et al. 2010).
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Figure 42: DMC-mediated death of MCF-7 cells did not appear to be apoptotic. MCF-7 cells
were treated with 50 μM etoposide (ETOP), 10 μM Mitomycin C (MC), and 10 μM 10decarbamoyl Mitomycin C (DMC) for 24, 48 and 72 hours. At the end of the treatments
Fluorescence activated cell sorting (FACS) was carried out. Cells were harvested, fixed in 30%
ethanol, and cellular DNA was stained with propidium iodide. Graphs show averages and
standard errors of two independent experiments.
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Though the DNA damaging drug, etoposide, and the Mdm2 small molecule inhibitor,
Nutlin-3, did not induce MCF-7 cell death, we observed that these drugs induced PARP cleavage
(Figure 43, compare lanes 1, 3 and 5). Since PARP cleavage is mediated by the caspases and is
indicative of the apoptotic pathway activation, this result suggests that etoposide and Nulin-3
treatments activated the caspase cascade pathway in the MCF-7 cells. Estrogen treatment
decreased drug-induced PARP cleavage (Figure 43, lanes 3-4 and 5-6), suggesting another role
estrogen may play in inhibiting apoptosis in the MCF-7 cells. This observation correlates with
our earlier observation that estrogen decreased the drug-induced Puma and in parallel increased
the Bcl-2 protein levels. To test whether estrogen inhibits apoptosis in MCF-7 cells and whether
Mdm2 plays a role in this process, the MCF-7 cells should be treated with MC (which robustly
induces apoptosis) in the absence and presence of estrogen and with or without Mdm2
knockdown.

Figure 43: Estrogen decreased basal and drug-induced PARP cleavage in MCF-7 cells. MCF7 cells were treated with 10 nM estrogen (E2) for five days, 50 μM etoposide (ETOP) for 48
hours and 10 μM Nutlin-3 (NUT) for 24 hours. Cleaved PARP and Actin protein levels from
whole cell lysates were analyzed by Western blot.
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In addition to inhibiting the etoposide-induced PARP cleavage, we also observed that
estrogen treatment decreased the basal and the etoposide-induced levels of the H2AX histone
phosphorylation. The H2AX phosphorylation on Ser 137 (called γH2AX) is indicative of the
double stand DNA damage and is important for the recruitment of repair factors to the DNA
damage sites (Paull et al. 2000). By Western blot analysis, we observed that estrogen treatment
decreased the basal protein level of γH2AX in the MCF-7 cells, while the total level of the
H2AX protein was not affected (Figure 44A, compare lanes 1 and 2). Similarly, estrogen
treatment decreased the basal γH2AX foci accumulation (Figure 44B, DMSO). Etoposide
treatment increased the protein levels of both H2AX and γH2AX (Figure 44A, compare lanes 1
and 3), but the increase of the γH2AX protein level was greater than that of the H2AX, 2.6 and
1.6 folds respectively (relative band intensities were determined by the ImageJ software).
Surprisingly, we did not observe an increase in foci formation after etoposide treatment by the
immunofluorescence method (Figure 44B, compare DMSO and ETOP in the absence of
estrogen). Importantly, estrogen treatment dramatically decreased etoposide-induced γH2AX
protein level and had no significant effect on the H2AX protein level (Figure 44A, compare lanes
3 and 4). Similarly, estrogen treatment decreased the γH2AX foci formation in etoposide-treated
cells (Figure 44B, ETOP).
This result is very interesting and suggests that estrogen either blocked double strand
DNA breaks formation after etoposide treatment or that estrogen blocked H2AX
phosphorylation, which, in turn, reduced the recruitment of repair factors to the DNA damage
sites. In the latter case, we can hypothesize that reduced γH2AX level in the presence of estrogen
can lead to cell cycle progression despite the DNA damage and thus result in accumulation of
genomic abnormalities and cancer development. Interestingly, earlier we observed that estrogen
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increased the nuclear protein levels of the Mdm2 protein in the absence and in the presence of
etoposide treatment. Therefore, it will be important to determine if the over-expression and the
nuclear accumulation of Mdm2 in the presence of estrogen play a role in the inhibition of H2AX
phosphorylation. By examining if estrogen can reduce the levels of γH2AX when Mdm2 is
knocked down, we could determine if the decrease in γH2AX is Mdm2-dependent.

Figure 44: Estrogen decreased basal and etoposide-induced H2AX phosphorylation in MCF-7
cells. MCF-7 cells were treated with 10 nM estrogen (E2) for five days and 50 μM etoposide
(ETOP) for 48 hours. (A) γH2AX (Ser-139) and H2AX protein levels from cell lysates by histone
extraction method were analyzed by Western blot. Total protein loading is shown by the
MemCode Stain (reversible protein stain). (B) γH2AX nuclear staining was visualized on
fluorescent microscope after indirect immunofluorescent staining of the γH2AX protein. Nuclear
DNA was stained with DAPI.
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4.5 Determine the downstream pathway(s) targeted by Mdm2 in the presence of estrogen.
Because our experiments indicate that the Mdm2 protein plays an important role in the
estrogen-mediated breast cancer cell proliferation, it is important to determine the downstream
pathway(s) that are targeted by Mdm2 in the presence of estrogen. The growth proliferative
effect of estrogen is largely attributed to the ability of estrogen to induce cell cycle progression
through the G1 to S transition (Lewis-Wambi and Jordan 2009). In addition to targeting the p21
cell cycle inhibitor, it is possible that the estrogen-mediated Mdm2 over-expression positively
affects cell cycle progression in the MCF-7 cells by targeting the Rb-E2F pathway. It has been
shown that estrogen promotes Rb phosphorylation thus stimulating proliferation of the G1arrested breast cancer cells (Altucci et al. 1996). In turn, the Mdm2 protein has been shown to
stimulate E2F transcriptional activity (Martin et al. 1995), disrupt the Rb-E2F complex (Sdek et
al. 2004) and promote Rb degradation (Sdek et al. 2005, Uchida et al. 2005). Therefore, the
effect of the Mdm2 protein on the Rb-E2F pathway in the presence of estrogen should be
examined.
In addition to studying the effect of Mdm2 over-expression on the Rb-E2F pathway in the
presence of estrogen, a study with a more general and holistic approach should be conducted.
There, it should be determined what Mdm2 signals to in the presence of estrogen to stimulate
cell proliferation. To achieve that, it is important to determine what proteins (and thus pathways)
are affected by the Mdm2 over-expression in the presence of estrogen. Proteins that will be
identified to be affected by Mdm2 over-expression and those that gain or lose their interactions
with Mdm2 in the presence of estrogen should be further characterized in reverse genetics
studies and the pathways in which these proteins are involved should be further addressed.
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